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ABSTRACT 
DIAGNOSTIC VALUE OF IMMUNOMARKERS IN 
CERVICAL CANCER SCREENING 
BACKGROUND: Carcinoma cervix is one of the leading causes of cancer deaths 
and lack of screening is found to be the major risk factor. Hence it is important to 
use screening methods which have better sensitivity.  
OBJECTIVE: The objective of our current study is to evaluate the diagnostic 
value of use of immunomarkers like p16INK4a and Ki-67 in cervical smears with 
HPE as gold standard and to assess their sensitivity and specificity in relation to 
cervical cytology.  
METHODS: We did immunostaining with p16INK4a and Ki-67 in liquid based 
cervical cytology sample and cervical biopsy specimens for 30 patients. p16INK4a is 
expressed in dysplastic cervical cells. Ki-67 is a proliferation marker. In cervical 
smears (immunocytochemistry), p16INK4a expression was graded as 0-negative, 1-
weakly positive and 2-strongly positive. Ki-67 expression was scored according to 
percentage of dysplastic cells showing nuclear positivity as follows (0-negative, 1-
<10%, 2-10-50% and 3->50% of dysplastic cells). In tissue sections 
(immunohistochemistry), p16 was interpreted as positive or negative and Ki-67 
expression was interpreted according to the thickness of epithelium involved. 
RESULTS: p16INK4a showed both nuclear and cytoplasmic staining and was 
positive in cervical smears of 81.8% of CIN I, 100% of CIN II, CIN III and 
malignant cases. All cervicitis cases were negative. All the CIN I cases showed 
weak staining, whereas high grade lesions and malignancy showed strong staining 
pattern. Ki-67 showed nuclear positivity. 54.5% of CIN I cases showed positivity 
in <10% of dysplastic cells, 60% of CIN II and 75% of CIN III cases showed 
positivity in 10-50% of dysplastic cells and 75% of malignant cases showed 
positivity in >50% of dysplastic cells. These associations were found to be 
statistically significant. The sensitivity for immunocytochemistry with p16INK4a and 
Ki-67 was 88.89% and 89.28% respectively, which were more than that for 
morphological interpretation in cervical cytology (77.78%). 
CONCLUSION: The use of immunomarkers in cervical smears has significantly 
increased the sensitivity of cervical cancer screening in our study. Hence steps 
should be taken to incorporate immunocytochemistry in cervical cancer screening 
in areas with better financial and laboratory resources. 
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INTRODUCTION 
 
 Carcinoma cervix ranks fourth among the leading causes of cancer in 
women worldwide, after carcinoma breast, colorectal carcinoma, and lung 
cancer. In developing countries like India, this accounts for the second most 
common cancer occurring in women and also the second leading cancer killer 
following carcinoma breast. Every year 528,000 new cases of carcinoma 
cervix are diagnosed. Of this one-fifth of cases occur in India(1). More 
importantly this affects women in the reproductive age group with median age 
of 38 years which adds to the social and economic burden(2). Of the three 
categories of cervical cancers which goes as squamous cell carcinoma, 
adenocarcinoma and other epithelial tumors, according to WHO classification, 
squamous cell carcinoma accounts for 75-80%(3). 
 
 Owing to the fact that cervical squamous cell carcinoma is almost 
always preceded by CIN (cervical intraepithelial neoplasia) lesions, long 
latency period and the availability of screening procedures, it is possible to 
diagnose cervical cancer in its pre-neoplastic stages. This has significantly 
reduced the burden of cervical cancer in high risk population. Therefore, 
cervical cancer has become one of the preventable causes of cancer morbidity 
and mortality. There are 3 intervention strategies used in cervical cancer 
screening which includes colposcopy, cervical cytology and cervical biopsy(4).  
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            According to ASCCP recommendations 2012, cancer screening should 
begin at the age of 21. This should be done every 3 years and continued upto 
the age of 65. HPV co-testing also can be included in screening. Despite the 
availability of these screening procedures, many are diagnosed only in the 
advanced stage. This is due to the limitations of cervical cytology (Pap smear) 
interpretation which are as follows, 
 
 Lack of objectivity in the morphologic criteria for grading CIN 
 Inter-observer variability 
 
  So to increase the diagnostic accuracy of the screening procedures, need 
for the use of biomarkers in cervical cytology has arisen now. The various 
biomarkers that can be used to improve the cervical cancer screening are as 
follows(4), 
 
 p16INK4a 
 Ki-67 
 Pro-Ex C 
 HPV L1 capsid 
 
 Cervical cytology has a high specificity of 97%-100%, but a low 
sensitivity of 50 to 70%. When biomarkers like p16INK4a and Ki-67 are used in 
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cervical cytology, the sensitivity of the screening procedure is increased to 
90%. 
 
 p16INK4a is a tumour suppressor protein and it inhibits cyclin-dependent 
kinase 4 and 6 which are regulatory proteins in cell cycle. So it is expressed in 
cervical dysplastic cells only. p16INK4a over-expression shows a positive 
correlation with HPV infection and degree of cervical neoplasia. Ki-67 is a 
marker of actively dividing cells. Therefore presence of p16INK4a and Ki-67 
positivity in cervical smear is a marker of cervical dyskaryosis(5). 
  
AIMS  
AND  
OBJECTIVES 
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AIMS AND OBJECTIVES 
1. To study the incidence and distribution of cervical pre-neoplastic and 
neoplastic lesions diagnosed by HPE at the Institute of Social Obstetrics 
and Govt. Kasturba Gandhi Hospital for Women and Children, Madras 
Medical College, during February 2014 to July 2014. 
2. To evaluate the diagnostic value of use of immunomarkers like p16INK4a 
and Ki-67in cervical smears with HPE as gold standard. 
3. To compare the expression of these markers in cervical smears with the 
morphological diagnosis in cervical cytology.  
4. To compare the expression of these markers and their inter-relationship 
in cervical pre-neoplastic and neoplastic lesions. 
5. To assess the association of intensity of expression of p16INK4a for 
grading the cervical pre-neoplastic and neoplastic lesions. 
6. To compare the expression of p16INK4a and Ki-67 in cervical smears 
(immunocytochemistry) in relation to expression of same markers in 
tissue sections (immunohistochemistry). 
 
 
 
  
 
REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
 
 Carcinoma cervix is one of the leading causes of cancer deaths 
occurring among Indian women. This mostly affects the reproductive age 
group with the median age of 38 years. Hence there is a must of preventing 
carcinoma cervix to reduce the socio-economic burden of developing 
countries.  
 
 It has been found that carcinoma cervix is almost always preceded by 
precursor lesions. This was first recognized by Sir John Williams in 1886 that 
areas adjacent to invasive squamous cell carcinoma show noninvasive 
dysplastic changes(6). Later Cullen found that these noninvasive lesions 
histologically resemble the invasive cancer(7). They are limited to the basement 
membrane and hence they are called as squamous intraepithelial lesions (SIL). 
They are graded according to the thickness of the squamous epithelium 
affected.  
 
 This led to the development of various screening procedures so that 
precancerous lesions of cervix can be detected at an early stage and treated and 
thus preventing the subsequent progression to invasive cancer in a wide range 
of population. Hence carcinoma cervix has now become one of the preventable 
causes of cancer morbidity and mortality. The incidence of carcinoma cervix 
also shows a steady decline worldwide owing to the availability of the 
screening procedures. 
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RISK FACTORS 
 The risk factors associated with precancerous lesions and carcinoma 
cervix are as follows: 
 
 Infection with high risk types of Human papillomavirus(8) 
 Age at first sexual intercourse 
 More than one sexual partner 
 Earlier age of first pregnancy 
 Multi-parity 
 Low socioeconomic status 
 Nutritional deficiency 
 Immunosuppression  
 Sexually transmitted diseases 
 Acquired immunodeficiency syndrome 
 Smoking(9) 
 Use of oral contraceptives 
 Inadequate screening 
 
 Among these, HPV infection and inadequate screening are considered 
the most important risk factors. 
 
 Smoking, OCP use and immunosuppression when combined with HPV 
infection double the risk of cervical cancer(9). 
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 Nutritional deficiency especially of micronutrients like folate, vitamin E 
is associated with increased cancer risk(13). 
 
 The mechanism behind the use of oral contraceptives is not clearly 
understood. 
 
 Low socioeconomic status is associated with early sexual intercourse, 
poor hygienic conditions, increased comorbid conditions and hence increases 
the risk of HPV infection. Presence of sexually transmitted disease favors the 
entry of Human papillomavirus into the basal cell layer of immature squamous 
epithelium. Use of condoms and male circumcision have shown to reduce the 
risk of HPV infection. Hence the incidence of cervical cancer is more in 
developing countries than developed countries. 
 
 Risk of persistence of HPV infection and its progression to neoplasia is 
increased in immunosuppressed individuals like post organ transplant 
recipients, patients affected by acquired immunodeficiency syndrome etc. 
 
 Thus all the risk factors mentioned above are interconnected and their 
combination further increases the cervical cancer risk. But adequate screening 
at regular intervals and proper treatment at right time can prevent cervical 
carcinoma. 
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ASSOCIATION OF HPV WITH CERVICAL CANCER 
 More than 80% of cervical squamous intraepithelial lesions are 
associated with Human papillomavirus infection. The association of cervical 
cancer with Human papillomavirus was first identified by Dr.Harald Zur 
Hausen who won Nobel prize in medicine in 2008(10).  Human 
papillomaviruses belong to the family Papillomaviridae. They have double 
stranded DNA containing 8000 base pairs, non-enveloped virion and a capsid. 
There are more than 118 types of papillomaviruses(10). They are highly species 
specific and are relatively tissue and site specific. Human papillomavirus 
belongs to the genus alpha-papillomavirus. Papillomaviruses are 
epitheliotrophic. They infect skin and mucous membrane and cause epithelial 
proliferations at the infection site. They are known to be associated with 
cancer cervix in most of the cases. They are also known to be associated with 
vulval, anal, penile and some of the head and neck squamous cell 
carcinomas(26). 
 
They are classified as following according to their oncogenic potential, 
Low risk types - 6, 11, 42, 43, 44, 53 
High risk types -16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 
Unclear oncogenic risk – 26, 68, 73, 82 
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 Among these, HPV 16 is the most common type encountered in LSIL 
(26%), HSIL (45.3%) and invasive cancers (70%). Next most common is HPV 
18. The other types associated are HPV 31, 33, 58 and 52.  
 
The viral genome is composed of three regions such as 
 Upstream regulatory region or Long Control Region (LCR) 
 Early region – E1, E2, E5, E6, E7 
 Late region – L1, L2 
 
 LCR is a non-coding region which controls the transcription of codons 
in the early region. Early region codes for the proteins required for viral 
replication and also codes for transforming genes like E5, E6 and E7(10). The 
late region codes for the structural proteins like L1 and L2(11). 
 
 E1 is an ATP dependent helicase which is required for initiation of viral 
replication in association with E2. E2 also acts as transcriptional repressor of 
E6 and E7 proteins. 
 
 E6 protein binds to p53 and causes its proteolytic degradation. p53 is a 
protein that causes cell cycle arrest at G1/S checkpoint by inducing the cell 
cycle inhibitor p21. So E7 protein by causing proteolytic degradation of p53, 
inhibits apoptosis and leads to cell cycle progression. 
 
10 
 
 E7 protein binds to Rb gene product which is a tumour suppressor 
protein, inhibits its function and thus leading to progression of cell cycle in an 
uncontrolled manner. It activates cyclin A and E and also inhibits cyclin 
dependent kinase inhibitors WAF-1 and p27, thus further augmenting the cell 
cycle progression. So overexpression of both E6 and E7 leads to uncontrolled 
cell proliferation and blockage of apoptosis.  
 
 Late coding region contains L1 and L2 which are viral capsid proteins 
and are produced late in the course of infection. 
 
 Human papillomavirus enters into the basal cell layer of squamous 
epithelium through defects in the epithelium. HPV may infect 
 
 Basal cells of exocervical portio 
 Basal cells of transformation zone 
 Reserve cells of endocervix 
 
 But mostly they begin in the squamo-columnar junction of the 
transformation zone. It involves the posterior lip than the anterior lip of the 
cervix. Those that involve the exocervical portio are of low grade and that of 
the endocervical canal are of high grade.  
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HPV produces two types of infections which are as follows, 
 Latent infection 
 Productive infection 
 
 Latent infection means the HPV genome resides freely inside the 
nucleus in circular form called episome and there is no replication. This does 
not induce any morphological changes in the cervical epithelium. The viral 
genome can only be detected by molecular methods. 
 
 Productive infection means the viral genome replicates independently 
that of the host genome and produces infectious virions and this occurs in the 
intermediate and superficial layers of the squamous epithelium, because HPV-
DNA replicates heavily in highly differentiated cells, that is the superficial 
layer. This produces HPV associated effects in the cells which can be seen 
both grossly and microscopically. The characteristic microscopic changes are 
as follows, 
 
 Acanthosis 
 Koilocytosis 
 Cytoplasmic vacuolization 
 Nuclear atypia 
 Multinucleation 
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 Most of the HPV infections are transient and resolve within one or two 
years(12). The persistence of HPV infections and its progression to cancer is 
associated with the following factors, 
 Persistence of HPV for longer duration 
 Infection with high risk types(9) 
 
 This strong association of carcinoma cervix with HPV led to the 
development of vaccine against HPV and HPV targeted therapies to cure even 
advanced stages of carcinoma cervix. 
 
 
PRECURSOR LESIONS OF SQUAMOUS CELL CARCINOMA OF 
CERVIX 
      The three systems of classification of cervical pre-neoplastic lesions are 
compared in the following table: 
Older classification WHO classification The Bethesda system 
Mild dysplasia CIN 1 LSIL(low grade squamous intraepithelial lesion) 
Moderate dysplasia CIN 2 HSIL(high grade squamous intraepithelial lesion) 
Severe dysplasia/ 
Carcinoma in situ CIN 3 HSIL 
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 Initially it was thought that dysplasia and carcinoma in situ were two 
different entities stating that dysplasia is a reversible condition and carcinoma 
in situ is a true neoplastic process.  
 
 Later, Richart said that all precursor lesions are monoclonal 
proliferations and are a single disease process and hence introduced the term 
cervical intraepithelial neoplasia (CIN)(14). CIN 1 corresponds to mild 
dysplasia, CIN 2 to moderate dysplasia, and CIN 3 to severe dysplasia and 
carcinoma in situ.  
 
 Zur Hausen et al found that Human papillomavirus is involved in the 
pathogenesis of cervical cancer and its precursor lesions(15). According to him, 
infection with HPV especially with high risk types leads to a precursor lesion 
and with persistence of infection, progresses to invasive cancer(16,17). Thus CIN 
1 indicates a productive viral infection that regresses in majority of cases, 
whereas CIN 2 or 3 indicates true neoplastic process, confined within the 
epithelium. Moreover LSIL is polyclonal and HSIL is monoclonal. This 
indicates that cervical carcinoma does not involve a step like process, 
progressing from CIN 1, to CIN 2, to CIN 3, and to invasive carcinoma. 
 
               CIN 1 or productive viral infection exhibits cytological changes 
commonly referred to as koilocytotic changes. This also includes flat and 
exophytic condylomas. They have high viral load. They share a common 
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ploidy status(19,20). Most of the cases are self-limited HPV infections even 
without treatment. 57% of CIN 1 cases regress spontaneously without 
treatment and 11% only progress to carcinoma. CIN 2 and CIN 3 lesions show 
high grade dysplastic changes and have the potential to progress to invasive 
squamous cell carcinoma if not treated(18). 43% of CIN 2 lesions regress and 
22% progress to carcinoma. With regard to CIN 3 lesions, 32% regress and 
12% progress to carcinoma(24). 
 
 Hence the new Bethesda system which is a two tier system came into 
vogue which categorized the lesions as LSIL (low grade squamous 
intraepithelial lesion) and HSIL (high grade squamous intraepithelial lesion). 
LSIL indicates CIN 1 or mild dysplasia and HSIL includes CIN 2 and CIN 3, 
otherwise called moderate dysplasia and severe dysplasia/ carcinoma 
insitu(21,22). 
 
 LSIL is most prevalent in the adolescent age group (15-19 years) and 
decreases in 25-40 year age group. Prevalence of HSIL steadily increases upto 
25-29 years and then decreases(23). Invasive carcinoma shows increased 
prevalence in 40-65 year age group. 
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PATHOLOGY OF PRECURSOR LESIONS 
CIN lesions are graded as follows, 
 CIN 1 – Neoplastic cells occupying the lower one-third of the 
epithelium. 
 CIN 2 - Neoplastic cells occupying lower one-third to two-third of 
the epithelium. 
 CIN 3 - Neoplastic cells occupying two-third to full thickness of the 
epithelium. 
 
Neoplastic cells show the following nuclear features, 
 Irregular nuclear membrane 
 Increased N:C ratio 
 Nuclear pleomorphism 
 Nuclear hyperchromatism 
 Coarse chromatin 
 
LSIL 
The features of LSIL are as follows, 
 Nuclear atypia in the lower one third of the epithelium. 
 Koilocytotic changes like cytoplasmic vacuolation, bi and 
multinucleation. 
 Architectural changes like papillomatosis and acanthosis. 
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 Koilocytotic changes are also seen in trichomoniasis, candidiasis etc., 
but they are not associated with nuclear atypia. 
 
HSIL 
The features of HSIL are as follows, 
 Nuclear atypia in more than one-third to full thickness of the epithelium 
 Nuclear crowding 
 Loss of polarity 
 Increased nuclear pleomorphism 
 Anisonucleosis 
 Abnormal mitotic figures (AMF) 
 Indistinct cell borders 
 
 Reparative and atrophic changes resemble HSIL and they are 
distinguished by strong and diffuse expression of p16 in all HSIL lesions. 
 
 These lesions can be managed colposcopically using cryosurgery, laser 
ablation and LEEP (loop electrosurgical excision procedure), thus preventing 
their progression to invasive carcinoma. For this screening becomes essential.  
 
INVASIVE SQUAMOUS CELL CARCINOMA 
 Carcinoma cervix most commonly affects women in their 40’s and 50’s, 
that is 20 years older than those affected by intraepithelial lesions(25). Human 
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papillomavirus infection is the most common risk factor and the most common 
types are HPV 16 and 18. There is a latency of 10 years between initial HPV 
infection and development of carcinoma cervix(26). 
 
 According to WHO classification, carcinoma cervix is divided into three 
categories as follows, 
 Squamous cell carcinoma 
 Adenocarcinoma 
 Other epithelial tumours 
 
 Of the above categories, squamous cell carcinoma accounts for more 
than 70-80% of cases. 
 
Squamous cell carcinoma is further divided into following types, 
 Microinvasive squamous cell carcinoma 
 Invasive squamous cell carcinoma 
 Keratinizing 
 Non keratinizing 
 Verrucous 
 Papillary 
 Warty 
 Basaloid 
 Squamo-transitional 
 Lymphoepithelioma like carcinoma 
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 There is often a long latency period between initial HPV infection and 
development of full fledge cervical cancer. Hence adequate screening and 
appropriate treatment at the initial stages can prevent the progression of 
precursor lesions to cervical cancer.  
 
CERVICAL CANCER SCREENING 
 Inadequate screening is the most important contributing factor to 
cervical cancer at the present scenario. Hence it is high time to make cervical 
cancer screening, a must for all women past 21 years to bring down the 
incidence of cervical cancer especially in developing countries.  
The objectives of cervical cancer screening are as follows, 
 To prevent morbidity and mortality of cervical cancer 
 To prevent over management of precursor lesions that in most cases 
regress 
The various screening modalities commonly used in developing countries at 
present are the following, 
 Cervical cytology – conventional 
 Cervical cytology – liquid based preparation 
 HPV testing 
 Colposcopy – VIA, VILI 
 Cervical biopsy 
 Immunomarkers 
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ASCCP 2012 GUIDELINES FOR CERVICAL CANCER 
SCREENING(30) 
 The current guidelines for cervical cancer screening according to 
ASCCP are as follows, 
 
 Screening should start at the age of 21 regardless of the age of sexual 
onset. 
 For ages 21-29 years, cytology alone is recommended every 3 years. 
HPV testing is neither employed as co-test nor as a primary screening 
test. 
 For ages 30-64 years, cytology and HPV co-testing together every 5 
years is preferable. Cytology alone every 3 years is also acceptable. But 
HPV testing alone is not recommended. 
 Screening should stop at 65 years even if the woman resumes sexual life 
with a new sexual partner, in case of  
 Adequate negative screening - 3 consecutive negative cytology 
or 2 consecutive negative HPV testing 
 No CIN II within the last 20 years 
 Screening can be stopped before 65 years in case of hysterectomy with 
removal of cervix without any prior history of CIN II. Adequate 
negative screening is not required. This is because, risk of Pap 
abnormality following hysterectomy is only 1%. 
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 In the presence of CIN II, CIN III, adenocarcinoma insitu, continue 
routine screening for atleast 20 years even past 65 years. 
 The above screening guidelines should not change for women who are 
vaccinated against HPV. 
 
 Most of the HPV infections are transient at 1-3 years interval and only 
persistent infection has the risk of progression to cervical cancer. Risk of 
HSIL/cancer after 3 years is not significantly higher than the risk after 1 year. 
Hence 3 years interval can be given between screening visits. 
 
 HPV testing is not needed in the 21-29 year age group because the 
prevalence of carcinogenic HPV in early 20’s is 20%, most of which disappear 
without intervention. HPV testing in this age group creates unnecessary 
anxiety and intervention and hence avoided. 
 
 HPV co-testing is added in 30-64 year age group because of increased 
prevalence of CIN III in this age group. Addition of HPV co-testing also 
reduces the number of colposcopies. However this cannot be done in all areas 
because of financial restrictions and hence cytology alone every 3 years is also 
acceptable in this age group. 
 
Screening should stop at 65 years because of the following reasons, 
 Risk of HPV infection is 5-10% 
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 Incident HPV infection is less likely to progress to cancer within the 
remaining lifetime. 
 Colposcopy/biopsy/treatment is difficult after this age group. 
 
MANAGEMENT ALGORITHMS ACCORDING TO ASCCP 
GUIDELINES 2012: (27) 
 For women with unsatisfactory cytology/ HPV negative, repeat cytology 
after 2-4 months. If again unsatisfactory, go for colposcopy. If 
unsatisfactory cytology/HPV positive, directly go for colposcopy. 
 
 For women with negative cytology/ HPV positive, go for either repeat 
co-testing after 12 months or can immediately go for HPV genotype 
testing for HPV 16/18. Direct colposcopy is not indicated because most 
infections regress within 12 months. If either the repeat co-test or HPV 
genotyping is positive, they are referred to colposcopy. If HPV 
genotyping is negative for 16/18, repeat co-test after 12 months. If both 
are negative, they can return to routine screening. 
 
 Women of 21-24 year age group with ASCUS or LSIL in cytology, 
should undergo repeat cytology yearly for 2 years. If both are negative, 
can continue with routine screening. If positive, should go for 
colposcopy. Even if reflex HPV test is positive, they should go for 
yearly cytology for 2 years. 
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 For women with ASCUS cytology/ HPV negative, continue routine 
screening because risk of CIN III in these patients is less than 2%. If 
ASCUS cytology/ HPV positive, go for colposcopy. If no HPV test is 
available, repeat cytology after 1 year and if negative, can continue with 
routine screening. 
 
 For women with LSIL/ HPV negative, go with repeat co-testing after 1 
year. If either of them is positive, go for colposcopy. If both are 
negative, continue with routine screening. If LSIL/ no HPV or positive 
HPV, go with colposcopy. 
 
 For pregnant women with LSIL, colposcopy is preferred. But deferring 
colposcopy till 6 weeks postpartum also is acceptable. 
 
 For women with ASC-H, go for colposcopy. 
 
 For women with HSIL, go either for colposcopy or directly immediate 
loop electrosurgical excision. LEEP is not recommended for women in 
21-24 year age group. 
 
 For women with biopsy proven CIN I preceded by lesser abnormalities, 
go for co-testing after 1 year. If either test is positive, go for colposcopy. 
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  For women with biopsy proven CIN I preceded by ASC-H or HSIL, go 
for diagnostic excision procedure. 
 
 For women with biopsy proven CIN 2 or 3, go for either excision or 
ablation of T-zone if adequate colposcopy. For inadequate colposcopy 
or recurrent CIN 2 or 3, go for excision. Then repeat co-testing at 12 and 
24 months. If 2 negative results, go for routine screening.  
 
 For young women with biopsy proven CIN 2 or 3, repeat colposcopy at 
6 months interval for 12 months. If abnormal, repeat biopsy. If CIN 2 or 
3 persists, go for treatment. 
 
CERVICAL CYTOLOGY 
 Cervical cytology is the most common and the most cost effective 
screening procedures available. Cervical cytology done twice in lifetime 
reduces risk of cervical cancer by 43% and yearly screening reduces risk by 
more than 90%(28,29). Despite screening, many women develop cervical cancer. 
The sensitivity of Pap smear is 40.2% and specificity is 90.6%(43). As for any 
other diagnostic or therapeutic techniques, cervical cytology also has its merits 
and demerits. There are two methods of cervical cytology, one is the 
conventional Pap smear and the other is the liquid based preparation. 
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METHODS OF CERVICAL CYTOLOGY 
The two methods of cervical cytology are as follows,  
 Conventional Pap smear 
 Liquid based cytology 
 
CONVENTIONAL PAP SMEAR 
 It was George Papaniculaou who first discovered that in patients with 
cervical carcinoma, tumour cells can be detected in vaginal fluid(32). 
Papaniculaou published in 1928, “New cancer diagnosis”(33). The merits and 
demerits of Pap smear are as follows, 
 
MERITS 
 No injury to the tissue even with repeated sampling. 
 Smears cover wider surface area than biopsy.  
 The procedure causes minimum shrinkage and distortion of cells and 
hence cellular details are clearly made out. 
 Effects of infection and irradiation on cellular morphology are easily 
made out. 
 
DEMERITS 
 The interpretation of morphology of cells is subjective and hence 
leads to inter-observer variation. 
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 The diagnosis in cytology is not taken as the final take. It has to be 
confirmed by histopathology for further management. 
 Large area has to be screened and hence it is time consuming. 
 The study is based on the morphology of exfoliated cells only. Hence 
it may not represent the lesion many a times. 
 The cells are often obscured by the inflammatory cells and also by 
haemorrhage related to the procedure. 
 Cellular arrangement or their inter-relationship cannot be studied. 
 The extent of invasion cannot be evaluated as only the cellular details 
are studied. 
 Size and site of the lesion cannot be assessed by cytology. 
 The smears cannot be used for further ancillary studies. 
 
LIQUID BASED CYTOLOGY 
 Here the material is not smeared onto the slide but rinsed into a liquid 
collection media containing fixatives, so that 100% of cells are preserved. The 
advantages of liquid based preparation over conventional Pap smear are as 
follows, 
 
MERITS OF LBC OVER CONVENTIONAL PAP SMEAR 
 Almost 100% of the collected cells are captured. 
 Immediate liquid fixation prevents air-drying. 
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 Easier to review slides. 
 Smaller screening area. 
 Reduced debris, cell clumps and obscuring elements and hence a 
cleaner background. So unsatisfactory cases are significantly 
reduced. 
 Increased detection of high-grade squamous intra-epithelial lesions 
and above. 
 Ancillary testing such as reflex Human papillomavirus (HPV) test, 
other molecular tests (Chlamydia/gonorrhoea) and 
immunocytochemistry can be performed from the residual material. 
 The residual material can also be processed as cell block. 
 
 
TRANSFORMATION ZONE 
          This is the area where the ectocervix meets the endocervix. This is the 
site of origin of squamous intra-epithelial lesions and squamous cell 
carcinomas. In adolescents and young adults, the transformation zone is on the 
surface of the ectocervix called as ectropion. In the reproductive age group, it 
is seen near the external os. In post-menopausal women, the transformation 
zone recedes into the endocervical canal. 
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NORMAL CELLS IN CERVICAL CYTOLOGY 
 The squamous epithelium of cervix and vagina are composed of 
three layers of cells 
 Superficial cells – large and flat with eosinophilic cytoplasm and 
pyknotic nuclei 
 Intermediate cells – large cells with cyanophilic to eosinophilic 
cytoplasm and small vesicular nuclei 
 Parabasal cells – singly dispersed with large uniform nuclei and 
distinct cytoplasmic borders 
 
 Squamous metaplasia – the cells have cytoplasmic processes and 
uniform pale nuclei with small nucleoli. 
 
 Endocervical cells – these cells are arranged in honeycomb sheet and 
when viewed from side, show picket fence appearance. They are 
columnar cells with vacuolated basophilic cytoplasm and basally 
located nuclei with fine chromatin and small nucleoli. 
 
 Endometrial cells – the cells are arranged in tight three-dimensional 
clusters. The cells have scant cytoplasm, small round dark nuclei 
showing no nucleoli. Superficial stromal cells are round and 
histiocytic. Deep stromal cells are spindled and dark. Exodus is seen 
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in 6 to 10 days of menstrual cycle. They consist of central core of 
stromal cells surrounded by epithelial cells. 
 
THE BETHESDA SYSTEM 2001(ANNEXUE IV) 
 In 1988, the Bethesda system was introduced so that uniform guidelines 
can be provided for reporting cervical cytology. This was later revised in the 
years 1991 and 2001(31). Terence J. Colgan has discussed the various sections 
of the Bethesda system 2001(34). The Bethesda system 2001 is given in 
annexure IV. 
 
SPECIMEN ADEQUACY(34) 
 SATISFACTORY 
 Conventional – minimum 8000-12000 well preserved and well 
visualised squamous cells 
 Liquid based cytology - ≥well preserved and well 
visualised squamous cells 
 For representation of transformation zone, 10 endocervical or 
squamous metaplastic cells should be present, not necessarily in 
clusters. But absence of this does not indicate it is 
unsatisfactory. 
 
 UNSATISFACTORY 
 Unlabelled vial or slide 
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 Broken slide 
 Blood, inflammation and other elements obscuring more than 
75% of the cells 
 
GENERAL CATEGORISATION 
 Negative for intraepithelial lesion 
 Epithelial cell abnormalities 
 Others  
NEGATIVE FOR INTRAEPITHELIAL LESION 
               According to Terence J. Colgan, >90% of Pap smears are negative 
for intraepithelial lesion(34). The causes are as follows. 
 Organisms  
- Trichomonas vaginalis 
- Candida 
- Bacterial vaginosis 
- Actinomyces 
- Cellular changes related to Herpes simplex virus 
 
 Reactive cellular changes associated with 
- Inflammation 
- Radiation 
- Atrophy 
- Intrauterine contraceptive device 
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EPITHELIAL CELL ABNORMALITIES(34) 
 Squamous cell abnormalities 
 Glandular cell abnormalities 
 Other 
 
SQUAMOUS CELL ABNORMALITIES(34) 
 The squamous cell abnormalities according to the Bethesda system 2001 
are classified as follows, 
 Atypical squamous cells 
- ASC-US 
- ASC-H 
 Low grade squamous intra-epithelial lesion 
 High grade squamous intra-epithelial lesion 
- HSIL with features suspicious for invasion 
 Squamous cell carcinoma 
 
 
ATYPICAL SQUAMOUS CELL OF UNDETERMINED 
SIGNIFICANCE (ASCUS) 
 ASCUS is a diagnosis of exclusion. This should not exceed >5% of all 
cytology specimens and should be more than twice of the SIL samples. ASC-
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US is the least reproducible diagnosis(37,38,39,40). The criteria for ASCUS 
according to the Bethesda system 2001are as follows(36). 
 Cells resemble superficial or intermediate squamous cells 
 Nuclei 2-3 times the size of a normal intermediate cell 
 Nuclei are normochromatic to slightly hyperchromatic with minimum 
irregularities. 
 
 
ATYPICAL SQUAMOUS CELLS, CANNOT EXCLUDE HSIL (ASC-H) 
 The features are suggestive of HSIL, but not all criteria are met to call it 
as HSIL(35) 
 Cells resemble basal or parabasal cells 
 Nuclei are irregular and hyperchromatic 
 
 
LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION (LSIL)(36) 
This includes both the HPV effects and mild dysplasia. 
 The cells resemble superficial or intermediate cell 
 Nuclei are 4-6 times the size of a normal intermediate cell nucleus 
 Bi- and multi-nucleation are common 
 Chromatin is finely granular and uniformly distributed 
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HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL)  
 This includes moderate dysplasia, severe dysplasia and also carcinoma 
in situ(35). The diagnosis of HSIL almost always indicates a risk for significant 
cervical disease(41,42). 
 Cells resemble basal or parabasal cells 
 Greatly increased nuclear cytoplasmic ratio 
 Hyperchromatic nucleus 
 Irregular nuclear contour 
 
 
INVASIVE SQUAMOUS CELL CARCINOMA 
 There are 2 types of squamous cell carcinoma, keratinizing and non-
keratinizing types. 
 
NON-KERATINIZING CARCINOMAS 
 Large number of cells that form syncytial sheets and loose clusters 
 Nuclei 2-3 times that of the intermediate cell nucleus 
 Coarse chromatin with focal clearing 
 Prominent macronucleoli 
 Tumour diathesis 
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KERATINIZING CARCINOMAS 
 Pleomorphic and tadpole shaped malignant cells 
 Abundant orangophilic cytoplasm 
 Hyperkeratosis and parakeratosis 
 No tumour diathesis 
 
 
HPV TESTING 
 The persistent detection of HPV in cervical cancer is a consistent 
feature(43). The risk of cervical cancer is increased with prolonged duration of 
HPV infection and specifically infection by high risk types like 16, 18 etc. The 
sensitivity of HPV DNA testing is 68.2% and specificity is 91.6%(43). In 
women under 30, HPV infection is transient and regresses and hence HPV co-
testing is done only after 30 years according to ASCCP guidelines 2012(30).  
 
The molecular techniques currently used are as follows, 
 Amplified methods 
 Signal amplification 
- The hybrid capture 2 HPV DNA assay 
 Target amplification 
- Polymerase chain reaction (PCR) 
 Non-amplified methods 
 The Southern blot hybridisation 
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COLPOSCOPY 
 According to ASCCP guidelines 2012, colposcopy is indicated only 
after repeated positive cytology especially in younger women(30). Hans 
Heinselmann was the one to introduce colposcopy in 1925, a method of 
identifying cervical lesions by illumination and magnification of the cervix(44). 
Schiller later introduced the concept of identifying cervical lesions by iodine 
application in 1928. This procedure has high sensitivity but low specificity. 
 
The merits of colposcopy as a screening procedure are as follows, 
 It is a relatively reliable procedure in developing countries 
 Simple and easy to perform 
 Maintenance is cheaper  
 Both diagnostic and therapeutic 
 
Visual inspection in colposcopy can be done by two methods, 
 VIA – Visual inspection with acetic acid 
 VILI – Visual inspection with Lugol’s iodine 
 
 After application of acetic acid, the abnormal cervical lesions turn 
acetowhite while the normal areas remain pink. This is because the density of 
white is proportional to the amount of cellular proteins. So the areas with 
highest proliferation and hence DNA content appear denser than the other 
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areas. The change in colour reverses quickly in case of inflammation, whereas 
slowly in case of CIN. 
 
          Similarly after application of Lugol’s iodine, abnormal areas do not take 
up the mahogany brown but take up saffron-yellow or mustard-yellow colour. 
The glycogen rich normal squamous epithelium takes up the mahogany brown 
colour. 
 
          The dense acetowhite area with VIA or the mustard yellow colored area 
with VILI are taken as positive when the lesion is in the transformation zone or 
around the squamo-columnar junction. Leopard skin like lesions (as seen in 
Trichomonas infection) and satellite lesions seen away from the squamo-
columnar junction are not taken as positive. 
 
          They can also be classified as low grade and high grade lesions. The 
acetowhite areas in high grade lesions are opaque and the iodine non-uptake 
lesions are thick and dense. 
 
CERVICAL BIOPSY 
 Cervical biopsy always remains the gold standard and as a confirmatory 
procedure for cervical pre-neoplastic and neoplastic lesions. This can be both 
diagnostic and therapeutic, because in many a cases, smaller abnormal lesions 
are completely removed. There are various methods of cervical biopsies which 
are as follows, 
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 Punch biopsy 
 Conisation 
 LLETZ (Large Loop Excision of the Transformation Zone) 
 
 In punch biopsy, small amount of tissue is removed with the help of a 
biopsy forceps. In conisation procedure, laser or a scalpel is used to remove 
large portions of cervix in the shape of a cone. In LLETZ, electric current 
through a wire loop is used for excision of cervical tissue. Thus these 
procedures are diagnostic as well as therapeutic and also remain the gold 
standard for the diagnosis of cervical pre-neoplastic and neoplastic lesions. 
 
IMMUNOMARKERS 
 The use of immunomarkers in cervical cytology is going to be the 
promising tool in the future in the screening for cervical cancer(45). Though 
there are certain morphological criteria laid down for grading the lesions 
according to the Bethesda system, this still lacks accuracy because of the inter-
observer variation. Immunocytochemistry can be used for triaging women with 
cervical dysplasia with increased accuracy.  
 
 The basic principle behind the use of immunomarkers in cytology and 
biopsy is unmasking the antigen in the cells and detecting them with the help 
of specific primary antibodies. 
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The various biomarkers that can be used in cervical cancer screening are, 
 p16INK4a 
 Ki-67 
 Pro-Ex C 
 HPV L1 Capsid 
 
p16INK4a 
 p16INK4a is a cellular protein involved in cell cycle control. Normally the 
Retinoblastoma protein is bound to elongation factor 2 and this pRb-E2F 
complex keeps the cell cycle in check. When they are bound together, the cells 
are in rest. They come apart to turn on the cell cycle and leads to mitosis. The 
cell cycle regulatory protein p16 is now expressed at lower levels, facilitates 
the binding of pRb to E2F and put the cell cycle back to rest(46).  
 
 With HPV infection, the viral DNA is introduced into the basal cells. 
But the viral DNA replicates in the superficial (more differentiated) cell layers 
and produces infectious virions. Most of the infections are transient and they 
do not affect the cell cycle control. But in transforming infections, the viral 
oncoprotein E7 begins to interfere in the cell cycle control. E7 protein binds to 
pRb, thus preventing the binding of E2F to pRb and holds the cell cycle 
permanently in the turn-on position and the cells continue to divide without 
any control. The cell cycle controller protein p16 is over-produced. Hence 
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increased expression of p16 has now become the marker of cervical 
carcinogenesis(46,47). 
 
Ki-67 
 Ki-67 is a nuclear antigen and is expressed during all phases of the cell 
cycle(48). Hence it is a proliferation marker that is normally expressed in 
parabasal cells in normal squamous epithelium. But in CIN lesions they get 
expressed in the stratified squamous epithelium according to the level of 
disordered maturation(46). Ki-67 expression is also seen in reactive changes and 
hence dual staining with p16 and Ki-67 is suggested. This provides higher 
sensitivity. 
 
Pro-Ex C 
 Pro-Ex C detects minichromosome maintenance proteins (MCMs)(46). 
They are required for DNA replication and hence are expressed in cervical pre-
neoplastic and neoplastic conditions. They are found to be negative in normal 
squamous epithelium and consistently positive in high grade cervical 
lesions(49,50).  
 
HPV L1 Capsid 
 The HPV proteins L1 and L2 are structural proteins. Of these L1capsid 
protein is the major protein on the surface of the virus. They are often 
expressed in productive viral infections(51,52), which usually occurs in 
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terminally differentiated cells. In CIN III and carcinomas, there is arrest of 
squamous maturation and hence are not expressed. HPV L1 capsid is usually 
used to assess the disease progression(53,54). 
 
The other markers that can be used for cervical cancer diagnosis are as 
follows, 
 Loss of E-cadherin expression (48) 
 CK17 negativity (55) 
 ER, PR (56) 
 Laminin(57) 
 Survivin(58) 
 
IMMUNOCYTOCHEMISTRY 
 According to a study done by Yoshida et al(59), the use of p16 as a 
biomarker in cervical cytology is more sensitive and specific than detecting 
HPV status. Hence immunocytochemistry using p16 can be used as a 
screening procedure in cervical pre-neoplastic and neoplastic lesions. For this 
liquid based preparations can be satisfactorily used. Dual staining with p16 and 
Ki-67 can also be done in cytology to increase the sensitivity. This allows 
early diagnosis even before colposcopy and cervical biopsy. This is a non-
invasive procedure with high sensitivity and specificity. Hence 
40 
 
immunocytochemistry is the future promising tool in cervical cancer 
screening. 
 
IMMUNOHISTOCHEMISTRY 
 All the above said markers can be used in tissue sections to confirm the 
morphological diagnosis. This is because many of the reactive process 
resemble dysplastic changes. To rule out all these reactive causes, 
immunohistochemistry, which has revolutionized the field of pathology is used 
in the diagnosis of cervical pre-neoplastic and neoplastic conditions. 
 
 
 
 
 
 
 
 
 
 
 
  
MATERIALS  
AND 
 METHODS 
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MATERIALS AND METHODS 
 
 This was a prospective study, conducted at the Institute of Social 
Obstetrics and Govt. Kasturba Gandhi Hospital for Women and Children, 
Madras Medical College from February 2014 to July 2014. 
 
               This study involved 30 women who had been diagnosed with positive 
VIA/VILI in colposcopy. These women were subjected to liquid based 
cervical cytology and cervical punch biopsy. Immunocytochemistry in the 
liquid based cytology sample and immunohistochemistry in cervical biopsy 
specimens using p16INK4a and Ki-67 were performed. The results of the above 
tests were compared with histopathology as the gold standard. 
 
               Also the incidence and distribution of cervical pre-neoplastic and 
neoplastic lesions diagnosed by HPE in our Institute from February 2014 to 
July 2014 were studied. 
 
INCLUSION CRITERIA 
1. Women in the age group of 21-65 years. 
2. Non-pregnant women. 
3. Women with positive VIA/VILI. 
4. Women without any prior treatment for cervical pre-neoplastic and 
neoplastic lesions. 
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EXCLUSION CRITERIA 
1. Pregnant women. 
2. Menstruating women. 
3. IUD user. 
4. Sexual intercourse with spermicidal jelly, douches/tampons 24 hours 
prior. 
5. Women who have undergone prior treatment for cervical pre-neoplastic 
and neoplastic lesions like cryotherapy, LLETZ, cervical biopsy, 
conisation, hysterectomy or radiation. 
 
VISUAL INSPECTION WITH ACETIC ACID AND LUGOL’S IODINE 
PROCEDURE 
1. The patient was put in lithotomy position and good visualization 
ensured. 
2. Any abnormality in external genitalia was recorded. 
3. Cusco’s speculum was inserted into the vagina and cervix was clearly 
visualised. 
4. Any discharge or mucus if present was wiped using a cotton swab wet 
with normal saline. 
5. External appearance of the cervix was recorded. 
6. Cervix was washed with freshly prepared 5% acetic acid using a 
syringe. 
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7. Then the cervix was observed for acetowhite areas after a one minute 
wait. 
8. Lugol’s iodine was applied onto the cervix with a syringe or a cotton 
swab. 
9. Cervix was observed for iodine uptake and non-uptake areas. 
10. All the findings were recorded. 
 
REPORTING 
NEGATIVE VIA/VILI 
 VIA - retention of pink hue 
 VILI - iodine uptake areas taking mahogany brown colour 
 
POSITIVE VIA/VILI 
 Low grade lesion 
 VIA - any acetowhite area 
 VILI - any iodine non-uptake area  
 High grade lesion 
 VIA - opaque acetowhite patches abutting the squamo-columnar 
junction 
 VILI - thick dense saffron-yellow or mustard-yellow iodine 
non-uptake areas around the squamo-columnar junction 
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 Invasive cancer 
 Irregular, ulcerative, proliferative growth which changes white 
with acetic acid and yellow with iodine application 
 
LIQUID BASED CYTOLOGY 
1. The patient was put in lithotomy position. 
2. Cervix was visualised using a Cusco’s speculum. 
3. The sample was taken using a cervical brush by rotating it 360° 
clockwise at the cervical os with the brush in contact with the 
ectocervix. The tip of the brush was broken and dropped into the alcohol 
based preservative fluid. 
4. The vial containing the tip of the brush was shaken with a vortex for 10 
seconds. 
5. Samples containing excess of mucus or blood were cleared with 4ml of 
clearing solution. 
6. Then the contents were poured into a 15ml centrifuge tube. 
7. Centrifugation was done for 1000g for 10 min. 
8. The supernatant was poured off and cell base reagent was added to the 
sample proportional to the cell pellet formed. 
9. A vortex was used to suspend the cell pellet. 
10. Then 50 microlitres of suspended cell pellet was pipetted onto a clean 
slide in the form of a circle. 
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11. The slides were air-dried and routine pap staining done. 
 
CYTOLOGYREPORTING 
 The cytology reporting was done based on the Bethesda system 2001as 
given in annexure IV. 
 
 
CERVICAL BIOPSY 
 Cervical biopsy was taken using punch biopsy forceps and put in 10% 
neutral buffered formalin and sent for histopathologic examination. The 
reports were given as  
 Normal 
 Chronic non-specific cervicitis 
 CIN I 
 CIN II 
 CIN III 
 Invasive squamous cell carcinoma 
- Well differentiated 
- Moderately differentiated 
- Poorly differentiated 
 Adenocarcinoma  
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IMMUNOCYTOCHEMISTRY 
 The remaining material in liquid based preparation was centrifuged and 
slides were prepared. Then immunocytochemistry was done using p16INK4a and 
Ki-67 in two separate slides using the procedure given in annexure V. The 
scoring was given as below. 
 
REPORTING 
p16INK4a scoring 
 p16 showed nuclear or cytoplasmic positivity or both. Scoring was 
given as follows based on intensity of staining(89). 
 
 0 - Negative  
 1 – Weakly positive in dysplastic cells 
 2 – Strongly positive in dysplastic cells 
 
Ki-67 scoring 
 Ki-67 showed nuclear positivity. Scoring was based on the percentage 
of dysplastic cells taking up the marker(88). 
 0 – Negative  
 1 –<10% of dysplastic cells positive 
 2 - 10-50% of dysplastic cells positive 
 3 - >50% of dysplastic cells positive 
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IMMUNOHISTOCHEMISTRY 
 The unstained sections were prepared from the cervical biopsy 
specimens and subjected to immunohistochemistry using the procedure given 
in annexure VI. 
 
REPORTING 
 p16INK4a 
The expression in cytoplasm or in nucleus or both were taken as 
positive(90), regardless of the intensity of staining. 
- 0 - negative 
- 1 - positive  
 
 Ki-67 
Ki-67 expression showed strong nuclear positivity in varying thickness 
of the stratified squamous epithelium and were graded as follows(91,92,93), 
- 0 – negative  
- 1 –nuclear positivity in lower-third of epithelium 
- 2 – nuclear positivity in lower two-thirds of epithelium 
- 3 – nuclear positivity in lower two-thirds to full thickness 
- 4 – diffuse nuclear positivity in the malignant cells 
 
 
 
48 
 
STATISTICAL ANALYSIS 
 The information collected and the reports of various screening 
modalities like colposcopy, cervical cytology, immunocytochemistry, cervical 
biopsy and immunohistochemistry were recorded in a master chart and they 
were compared with each other. 
 
 The P value was calculated for liquid based cervical cytology, 
immunocytochemical expression of p16 and Ki-67 in cervical non-neoplastic, 
pre-neoplastic and neoplastic lesions, showing their statistical significance in 
correlation with biopsy. The sensitivity, specificity, positive predictive value 
and negative predictive value were also calculated and they were compared 
with other similar studies. 
 
 The incidence and distribution of cervical pre-neoplastic and neoplastic 
lesions diagnosed by HPE from February 2014 to July 2014 in our Institute 
were studied. The distribution of cervical pre-neoplastic and neoplastic lesions 
in relation to various clinicopathological factors like age, menstrual status, 
quadrant of cervix involved were also studied. 
 
 
 
 
  
 
OBSERVATION  
AND  
RESULTS 
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OBSERVATION AND RESULTS 
 
               This was a prospective study conducted in the Institute of Social 
Obstetrics and Govt. Kasturba Gandhi Hospital for Women and Children, 
Madras Medical College, from February 2014 to July 2014.  
 
EPIDEMIOLOGY OF CERVICAL PRE-NEOPLASTIC AND 
NEOPLASTIC LESIONS IN OUR INSTITUTE  
(FEBRUARY 2014 TO JULY 2014) 
 
 In a 6 months period from February 2014 to July 2014, totally 202 cases 
were reported as cervical pre-neoplastic and neoplastic lesions by HPE. Of the 
202 cases, 139(68.8%) were CIN I, 19(9.4%) were CIN II, 11(5.4%) were CIN 
III and 33(16.3%) were malignancies (table 1 and chart 1). 
 
TABLE 1 
DISTRIBUTION OF CERVICAL PRE-NEOPLASTIC AND 
NEOPLASTIC LESIONS 
n=202 
BIOPSY CIN I CIN II CIN III MALIGNANCY
FREQUENCY 139 19 11 33 
PERCENTAGE 68.8% 9.4% 5.4% 16.3% 
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 The distribution of subtypes of SCC and adenocarcinoma among the 
malignant cases is given in table 2 and chart 2. SCC-WD constitutes 63.6%, 
SCC-MD constitutes 30.3%, SCC-PD constitutes 3% and adenocarcinoma 
(adenoca) constitutes 3%. 
 
TABLE 2  
 DISTRIBUTION OF MALIGNANT CERVICAL LEISONS 
n=33 
BIOPSY SCC-WD SCC-MD SCC-PD ADENOCA 
FREQUENCY 21 10 1 1 
PERCENTAGE 63.6% 30.3% 3% 3% 
 
 
 Age-wise distribution of cervical pre-neoplastic and neoplastic lesions is 
given in table 3 and chart 3. All CIN lesions were common in the 31-40 year 
age group. All malignant cases were common in the 51-60 year age group. 
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TABLE 3  
AGE-WISE DISTRIBUTION OF CERVICAL PRE-NEOPLASTIC AND 
NEOPLASTIC LESIONS 
n=202 
BIOPSY 
AGE (YEARS) 
21-30 31-40 41-50 51-60 61-70 
CIN I - 139 27(19.4%) 70(50.4%) 38(27.3%) 4(2.9%) 0 
CIN II – 19 5(26.3%) 9(47.4%) 2(10.5%) 2(10.5%) 1(5.3%) 
CINIII - 11 1(9.1%) 6(54.5%) 2(18.2%) 2(18.2%) 0 
MALIG - 33 0 3(9.1%) 12(36.4%) 14(42.4%) 4(12.1%)
 
 The distribution of menstrual status in cervical pre-neoplastic and 
neoplastic lesions is given in table 4. More than 70% of CIN lesions occur in 
reproductive women. More than 90% of malignant lesions occur in post-
menopausal women. 
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TABLE 4  
DISTRIBUTION OF CERVICAL PRE-NEOPLASTIC AND 
NEOPLASTIC LESIONS – MENSTRUAL STATUS WISE 
n=202 
BIOPSY 
MENSTRUAL STATUS 
REPRODUCTIVE POST-MENOPAUSAL 
CIN I - 139 123(88.5%) 16(11.5%) 
CIN II – 19 14(73.7%) 5(26.3%) 
CINIII - 11 9(81.8%) 2(18.2%) 
SCC - 32 3(9.4%) 29(90.6%) 
ADENOCA - 1 0 1(100%) 
 
               The distribution of cervical pre-neoplastic and neoplastic lesions in 
colposcopic biopsies according to quadrant of cervix involved is given in table 
5 and chart 4. Most of the lesions were seen around 12 o’ clock position. All 
invasive carcinomas were seen circumferentially abutting the os. 
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TABLE 5 
DISTRIBUTION OF CERVICAL PRE-NEOPLASTIC AND 
NEOPLASTIC LESIONS IN COLPOSCOPIC BIOPSIES – QUADRANT 
OF CERVIX INVOLVED WISE 
n=170 
BIOPSY 
QUADRANT OF CERVIX (o’ clock) 
12-3 3-6 6-9 9-12 CIRCUM 
CIN I 70(56.9%) 21(17.1%) 11(9%) 21(17.1%) 0 
CIN II 11(73.3%) 2(13.3%) 0 1(6.7%) 1(6.7%) 
CIN III 3(50%) 0 1(16.7%) 1(16.7%) 1(16.7%) 
SCC 1(4%) 0 0 0 24(96%) 
ADENOCA 0 0 0 0 1(100%) 
 
 
CHARACTERISTICS OF THE CURRENT STUDY GROUP 
               30 VIA/VILI positive cases were randomly selected from the patients 
attending the colposcopy department for our study. Of these, 15 were low 
grade lesions (LGL), 10 were high grade lesions (HGL) and 5 were invasive 
carcinoma (inv ca) by VIA/VILI (table 6). 
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TABLE 6  
DISTRIBUTION OF VIA/VILI DIAGNOSIS IN THE STUDY GROUP 
n=30 
VIA/VILI LGL HGL INV CA 
FREQUENCY 15 10 5 
PERCENTAGE 50% 33.3% 16.7% 
 
 These 30 patients were subjected to liquid based cytology and cervical 
biopsy. The biopsy report was the confirmatory diagnosis. So it was taken as 
the gold standard. Of these 30 VIA/VILI positive cases, the biopsy results 
turned out to be 2 chronic cervicitis, 11 CIN I, 5 CIN II, 4 CIN III and 8 SCC 
cases (table 7 and chart 5). 
 
TABLE 7 : BIOPSY RESULTS 
n=30 
BIOPSY DIAGNOSIS NUMBER OF CASES PERCENTAGE 
CHRONIC CERVICITIS 2 6.7% 
CIN I 11 36.7% 
CIN II 5 16.7% 
CIN III 4 13.3% 
SCC 8 26.7% 
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               In this study group, the age wise distribution of biopsy diagnosis is as 
follows. 2 patients diagnosed with chronic cervicitis were in the 21-30 year 
age group. Majority of CIN I (54.5%) and CIN III (50%) lesions were in the 
31-40 year age group. CIN II cases were more or less equally distributed 
among all the age groups here. All cases of squamous cell carcinomas were 
above 40 years (table 8 and chart 6). 
TABLE 8 
AGEWISE DISTRIBUTION OF BIOPSY RESULTS IN THE STUDY 
GROUP 
n=30 
BIOPSY 
DIAGNOSIS 
AGE(YEARS) 
21-30 31-40 41-50 51-60 
CERVICITIS 2(100%) 0 0 0 
CIN I 2(18.2%) 6(54.5%) 3(27.3%) 0 
CIN II 2(40%) 1(20%) 1(20%) 1(20%) 
CIN III 0 2(50%) 1(25%) 1(25%) 
SCC 0 0 4(50%) 4(50%) 
 
               Majority of the cervical non-neoplastic and pre-neoplastic lesions 
were seen in reproductive women in this study group. But all the squamous 
cell carcinoma cases were seen in the post-menopausal women (table 9).      
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TABLE 9  
DISTRIBUTION OF BIOPSY RESULTS IN THE STUDY GROUP – 
MENSTRUAL STATUS WISE 
n=30 
BIOPSY 
MENSTRUAL STATUS 
REPRODUCTIVE POST-MENOPAUSAL 
CERVICITIS 2(100%) 0 
CIN I 10(90.9%) 1(9.1%) 
CIN II 3(60%) 2(40%) 
CIN III 3(75%) 1(25%) 
SCC 0 8(100%) 
 
 
 The distribution of cervical non-neoplastic, pre-neoplastic and 
neoplastic lesions according to the quadrant of cervix involved is given in table 
10. Majority of lesions were in the 12-3 o’ clock quadrant. All the carcinoma 
cases were seen all around abutting the os. 
57 
 
 
TABLE 10 
DISTRIBUTION OF BIOPSY RESULTS IN THE STUDY GROUP – 
QUADRANT OF CERVIX INVOLVED WISE 
n=30 
BIOPSY 
QUADRANT OF CERVIX INVOLVED (o’ clock) 
12-3 3-6 6-9 9-12 Circum- ferential 
CERVICITIS 1 0 0 1 0 
CIN I 8 2 0 1 0 
CIN II 3 0 0 1 1 
CIN III 2 0 1 0 1 
SCC 0 0 0 0 8 
 
               15 low grade lesions (LGL) in VIA/VILI turned out to be cervicitis – 
2, CIN I – 10, CIN II – 3 in biopsy. So 2 were false negative by VIA/VILI.10 
high grade lesions (HGL) in VIA/VILI turned out to be CIN I – 1, CIN II – 2, 
CIN III – 4 and SCC – 3 in biopsy. 3 squamous cell carcinomas were 
underestimated as high grade lesions in VIA/VILI. All the 5 invasive 
carcinomas were reported as squamous cell carcinoma in biopsy. This is given 
in table 11 and chart 7. 
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TABLE 11 
COMPARISON OF VIA/VILI WITH BIOPSY DIAGNOSIS 
n=30 
 
VIA/VILI 
BIOPSY REPORT 
CERVICITIS CIN I CIN II CIN III SCC 
LGL=15 2(100%) 10(90.9%) 3(60%) 0 0 
HGL=10 0 1(9.1%) 2(40%) 4(100%) 3(37.5%) 
INV CA=5 0 0 0 0 5(62.5%) 
 
              The percentage of concordance for VIA/VILI with biopsy was 66.7% 
for LGL, 90% for HGL and 100% for SCC (table 12). 
 
TABLE 12 
PERCENTAGE OF CONCORDANT CASES IN VIA/VILI 
VIA/VILI LGL HGL INV CA 
TOTAL 15 10 5 
CONCORDANT 10 9 5 
% OF 
AGREEMENT 66.7% 90% 100% 
 
               These patients were subjected to liquid based cervical cytology. The 
reports were given as NIL – 6, LSIL – 10, HSIL – 8, SCC – 6 (table 13). 
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TABLE 13 :  LBC RESULTS 
n=30 
LBC NIL LSIL HSIL SCC 
FREQUENCY 6 10 8 6 
PERCENTAGE 20% 33.3% 26.6% 20% 
 
 Of the 15 low grade lesions reported by VIA/VILI, 6 were reported as 
NIL and 9 as LSIL in LBC. Of the 10 high grade lesions, 1 was reported as 
LSIL, 8 as HSIL and 1 as SCC. All the 5 invasive carcinomas in VIA/VILI 
were reported as SCC in LBC (table 14). 
 
TABLE 14 : COMPARISON OF LBC WITH VIA/VILI 
n=30 
VIA/VILI 
LBC REPORTS 
NIL LSIL HSIL SCC 
LGL=15 6 9 0 0 
HGL=10 0 1 8 1 
INV CA=5 0 0 0 5 
 
               The 6 NIL cases turned out to be 2 cervicitis and 4 CIN I by biopsy. 
10 LSIL cases turned out to be 7 CIN I and 3 CIN II. 9 HSIL cases turned out 
to be 2 CIN II, 4 CIN III and 3 SCC in biopsy. All 5 SCC cases were proved to 
be SCC only (table 15 and chart 8). 
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TABLE 15  
COMPARISON OF LBC WITH BIOPSY 
n=30 
LBC 
BIOPSY DIAGNOSIS 
CERVICITIS CIN I CIN II CIN III SCC 
NIL 2(100%) 4(36.4%) 0 0 0 
LSIL 0 7(63.6%) 3(60%) 0 0 
HSIL 0 0 2(40%) 4(100%) 2(25%) 
SCC 0 0 0 0 6(75%) 
 
                The percentage of concordance for LBC with biopsy was 33.3% for 
NIL, 70% for LSIL, 75% for HSIL and 100% for SCC (table 16). 
 
TABLE 16 
PERCENTAGE OF CONCORDANT CASES IN LBC 
LBC NIL LSIL HSIL SCC 
TOTAL 6 10 8 6 
CONCORDANT 2 7 6 6 
%  OF 
AGREEMENT 33.3% 70% 75% 100% 
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TABLE 17 : NUMBER OF TRUE POSITIVES, FALSE POSITIVES, 
TRUE NEGATIVES AND FALSE NEGATIVES IN LBC 
LBC 
BIOPSY 
POSITIVE NEGATIVE 
POSITIVE TP(14) FP(0) 
NEGATIVE FN(4) TN(2) 
 
Sensitivity = 77.78% 
Specificity = 100% 
Positive predictive value = 100% 
Negative predictive value = 33.33% 
 
 The correlation of LBC report with biopsy diagnosis showed a P value 
of 0.000 (table 18). 
 
TABLE 18 
CORRELATION OF LBC INTERPRETATION WITH HPE 
DIAGNOSIS 
LBC 
BIOPSY DIAGNOSIS P 
value CERVICITIS CIN I CIN II CIN III SCC 
NIL 2 4 0 0 0 
0.000 
LSIL 0 7 3 0 0 
HSIL 0 0 2 4 2 
SCC 0 0 0 0 6 
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 p16 showing expression in nucleus or cytoplasm or both were taken as 
positive. The expression of p16 in cervical smears (ICC) was reported as 
negative, weakly positive and strongly positive. The results were 4 negative 
cases, 12 weakly positive cases and 14 strongly positive cases (table 19). 
 
TABLE 19 
IMMUNOCYTOCHEMISTRY - p16 RESULTS 
n=30 
ICC – p16 NEGATIVE WEAKLY + STRONGLY + 
FREQUENCY 4 12 14 
PERCENTAGE 13.3% 40% 46.7% 
 
 
 Among the 6 NIL cases diagnosed by LBC, 4 cases showed negativity 
with p16 and 2 showed weak positivity. Among the 10 LSIL cases, 9 cases 
showed weak positivity and 1 showed strong positivity. Among the 8 HSIL 
cases, 1 showed weak positivity and 7 cases showed strong positivity. All 6 
carcinoma cases showed strong positivity with p16 (table 20 and chart 9). 
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TABLE 20 : COMPARISON OF EXPRESSION OF p16 IN CERVICAL 
SMEARS WITH MORPHOLOGICAL DIAGNOSIS IN LBC 
n=30 
LBC 
ICC – p16 
NEGATIVE WEAK + STRONG + 
NIL 4(66.7%) 2(33.3%) 0 
LSIL 0 9(90%) 1(10%) 
HSIL 0 1(12.5%) 7(87.5%) 
SCC 0 0 6(100%) 
 
               All cervicitis cases showed negativity with p16 in cervical smears. 
81.81% of CIN I and 100% of CIN II, CIN III and SCC cases showed 
positivity with p16 in ICC (table 21 and chart 10). 
 
TABLE 21 
COMPARISON OF p16 EXPRESSION (ICC) WITH BIOPSY 
n=30 
ICC – p16 
BIOPSY 
CERVICITIS CIN I CIN II CIN III SCC 
NEGATIVE 2(100%) 2(18.18%) 0 0 0 
WEAK + 0 9(81.81%) 2(40%) 1(25%) 0 
STRONG + 0 0 3(60%) 3(75%) 8(100%) 
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TABLE 22 : NUMBER OF TRUE POSITIVES, FALSE POSITIVES, 
TRUE NEGATIVES AND FALSE NEGATIVES IN ICC-p16 
ICC – p16 
BIOPSY 
POSITIVE NEGATIVE 
POSITIVE TP(16) FP(0) 
NEGATIVE FN(2) TN(2) 
 
Sensitivity = 88.89% 
Specificity = 100% 
Positive predictive value = 100% 
Negative predictive value = 50% 
 
 The association of p16 expression in cervical non-neoplastic, pre-
neoplastic and neoplastic lesions showed P value of 0.000 (table 23). 
 
TABLE 23  
CORRELATION OF p16 EXPRESSION IN CERVICAL SMEARS 
(ICC) WITH BIOPSY DIAGNOSIS 
ICC – p16 
BIOPSY P value
CERVICITIS CIN I CIN II CINIII SCC 
 
0.000 
 
NEG 2 2 0 0 0 
WEAK + 0 9 2 1 0 
STRONG+ 0 0 3 3 8 
 
65 
 
 All the 9 CIN I cases showed weak positivity with p16 in dysplastic 
cells. Among the 5 CIN II cases, 2 were weakly positive and 3 were strongly 
positive. Among the 4 CIN III cases, 1 was weakly positive and 3 were 
strongly positive. All the 8 SCC cases showed strong positivity. The 
correlation of increasing intensity of p16 expression in cervical pre-neoplastic 
and neoplastic lesions showed P value of 0.000 (table 24). 
 
TABLE 24 : CORRELATION OF INTENSITY OF p16 EXPRESSION 
(ICC) WITH INCREASING GRADES OF CERVICAL LESIONS 
 
ICC – p16 
BIOPSY P value 
CIN I CIN II CIN III SCC 
0.000 WEAK 9 2 1 0 
STRONG 0 3 3 8 
 
               The results of Ki-67 expression in cervical smears are given in table 
25. Ki-67 showed nuclear positivity. As even normal proliferating basal cell 
layer of cervical lining shows positivity with Ki-67, <1% of normal cells 
showing positivity was taken as negative. The scores were given as 0 if 
negative, score of 1 if <10% of dysplastic cells were positive , score of 2 if 10-
50% of dysplastic cells were positive and score of 3 if >50% of dysplastic cells 
were positive. Here, 5 cases were negative, 7 cases showed positivity in <10% 
of dysplastic cells, 10 cases showed positivity in 10-50% of dysplastic cells 
and 8 cases showed positivity in >50% of dysplastic cells. 
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TABLE 25 : IMMUNOCYTOCHEMISTRY – Ki67 RESULTS 
n=30 
ICC - Ki-67 NEG <10% 10-50% >50% 
FREQUENCY 5 7 10 8 
PERCENTAGE 16.7% 23.3% 33.3% 26.7% 
 
 Among the 6 NIL cases diagnosed by LBC, 5 were negative for Ki-67 
and 1showed positivity in <10% of dysplastic cells. Among the 10 LSIL cases, 
6 showed positivity in <10% of dysplastic cells and 4 showed positivity in 10-
50% of dysplastic cells. Among the 8 HSIL cases, 5 showed positivity in 10-
50% of dysplastic cells and 3 showed positivity in >50% of dysplastic cells. 
Among the 6 SCC cases, 1 showed positivity in 10-50% of dysplastic cells and 
5 showed positivity in >50% of dysplastic cells (table 26 and chart 11).  
 
TABLE 26 : COMPARISON OF EXPRESSION OF Ki-67 IN 
CERVICAL SMEARS WITH MORPHOLOGICAL  
DIAGNOSIS IN LBC 
LBC 
ICC – Ki67 
NEGATIVE <10% 10-50% >50% 
NIL 5(83.3%) 1(16.7%) 0 0 
LSIL 0 6(60%) 4(40%) 0 
HSIL 0 0 5(62.5%) 3(37.5%) 
SCC 0 0 1(16.7%) 5(83.3%) 
 
67 
 
               2 cervicitis cases diagnosed by biopsy were negative. Of the 11 CIN I 
cases, 8 cases (72.7%) showed positivity, of which 6 showed positivity in 
<10% of dysplastic cells and 2 showed positivity in 10-50% of dysplastic cells. 
All the CIN II cases showed positivity, of which 1showed positivity in <10% 
of dysplastic cells, 3showed positivity in 10-50% of dysplastic cells and 1 
showed positivity in >50% of dysplastic cells. All the 4 CIN III cases showed 
positivity, of which 3 showed positivity in 10-50% of dysplastic cells and 1 
showed positivity in >50% of dysplastic cells. All the 8 SCC cases were 
positive, of which 2 showed positivity in 10-50% of dysplastic cells and 6 
showed positivity in >50% of dysplastic cells (table 27 and chart 12). 
 
 
TABLE 27 : COMPARISON OF Ki67 EXPRESSION IN CERVICAL 
SMEARS (ICC) WITH HPE 
ICC – 
Ki67 
BIOPSY 
CERVICITIS CIN I CIN II CIN III SCC 
NEG 2(100%) 3(27.3%) 0 0 0 
<10% 0 6(54.5%) 1(20%) 0 0 
10-50% 0 2(18.2%) 3(60%) 3(75%) 2(25%) 
>50% 0 0 1(20%) 1(25%) 6(75%) 
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TABLE 28: NUMBER OF TRUE POSITIVES, FALSE POSITIVES, 
TRUE NEGATIVES AND FALSE NEGATIVES IN ICC-Ki67 
ICC – Ki67 BIOPSY 
POSITIVE NEGATIVE 
POSITIVE TP(25) FP(0) 
NEGATIVE FN(3) TN(2) 
 
Sensitivity = 89.28% 
Specificity = 100% 
Positive predictive value = 100% 
Negative predictive value = 40% 
 
 The association of percentage of dysplastic cells expressing Ki-67 in 
cervical smears in cervical non-neoplastic, pre-neoplastic and neoplastic 
lesions showed P value of 0.000 (table 29). 
 
TABLE 29 : CORRELATION OF Ki67 EXPRESSION IN CERVICAL 
SMEARS (ICC) WITH HPE 
ICC – 
Ki67 
BIOPSY P value 
CERVICITIS CIN I CIN II CINIII SCC 
 
0.000 
NEG 2 3 0 0 0 
<10% 0 6 1 0 0 
10-50% 0 2 3 3 2 
>50% 0 0 1 1 6 
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               The results of p16 expression in tissue sections is given in table 30. 
p16 showed nuclear or cytoplasmic positivity or both. 26 cases were positive 
and 4 were negative. 
 
TABLE 30 : IMMUNOHISTOCHEMISTRY – p16 RESULTS 
n=30 
IHC – p16 POSITIVE NEGATIVE 
FREQUENCY 26 4 
PERCENTAGE 86.7% 13.3% 
 
 All cervicitis cases showed negativity with p16 in IHC. Among the 11 
CIN I cases, 9 showed positivity and 2 were negative. All the 5 CIN II cases 
showed positivity for p16. All the 4 CIN III cases showed positivity for p16. 
All the 8 SCC cases showed positivity for p16 (table 31 and chart 13). 
 
TABLE 31 : COMPARISON OF p16 EXPRESSION (IHC) WITH 
BIOPSY 
 n=30 
IHC – p16 
BIOPSY 
CERVICITIS CIN I CIN II CIN III SCC 
NEGATIVE 2(100%) 2(18.2%) 0 0 0 
POSITIVE 0 9(81.8%) 5(100%) 4(100%) 8(100%) 
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 The association of immunohistochemical expression of p16 in cervical 
non-neoplastic, pre-neoplastic and neoplastic lesions showed P value of 0.003 
(table 32). 
 
TABLE 32 
CORRELATION OF IMMUNOHISTOCHEMICAL  
p16 EXPRESSION WITH BIOPSY 
 
IHC – p16 
BIOPSY P value 
CERVICITIS CIN I CINII CINIII SCC 
0.003 NEGATIVE 2 2 0 0 0 
POSITIVE 0 9 5 4 8 
 
 
 The positivity and negativity of p16 expression in ICC and IHC were 
compared in relation to cervical lesions. All cases showed 100% concordance 
with IHC (table 33). 
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TABLE 33 : COMPARISON OF EXPRESSION OF p16 IN ICC AND 
IHC IN RELATION TO CERVICAL LESIONS 
p16 
BIOPSY 
CERVICITIS CIN I CIN II CIN III SCC 
1CC IHC ICC IHC ICC IHC ICC IHC ICC IHC
POS 0 0 9 9 5 5 4 4 8 8 
NEG 2 2 2 2 0 0 0 0 0 0 
% of 
agreement 100% 100% 100% 100% 100% 
 
  
       The results of Ki67 expression in tissue sections is given in table 34. 
Cases expressing Ki-67 nuclear positivity in the basal layer was taken as 
negative as it is normal. Only those cases expressing Ki-67, 2 layers above the 
basal layer were considered positive.  
 
TABLE 34 : IMMUNOHISTOCHEMISTRY – Ki-67 RESULTS 
n=30 
IHC – Ki67 Neg Lower 1/3 
Lower 
2/3 
Full 
thickness Diffuse 
FREQUENCY 4 9 5 4 8 
PERCENTAGE 13.3% 30% 16.7% 13.3% 26.7% 
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 2 cases of cervicitis were negative. Of the 11 CIN I cases, 2cases were 
negative and the remaining 9 cases showed nuclear positivity in lower 1/3rd of 
the epithelium. All the 5 CIN II cases showed nuclear positivity in lower 2/3rd 
of the epithelium. All the 4 CIN III cases showed nuclear positivity in full 
thickness of the epithelium. All the 8 SCC cases showed diffuse nuclear 
positivity in the malignant cells including the invasive component (table 35 
and chart 14). 
TABLE 35 
COMPARISON OF Ki67 EXPRESSION IN  
TISSUE SECTIONS (IHC) WITH BIOPSY 
n=30 
IHC – 
Ki67 
BIOPSY 
CERVICITIS CIN I CIN II CIN III SCC 
Neg 2(100%) 2(18.2%) 0 0 0 
lower 1/3 0 9(81.9%) 0 0 0 
lower 2/3 0 0 5(100%) 0 0 
Full 
thickness 
0 0 0 4(100%) 0 
Diffuse  0 0 0 0 8(100%) 
 
              The association of thickness of epithelium showing Ki-67 expression 
in tissue sections in cervical non-neoplastic, pre-neoplastic and neoplastic 
lesions showed P value of 0.000 (table 36).
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TABLE 36 
CORRELATION OF Ki-67 EXPRESSION IN TISSUE SECTIONS 
(IHC) WITH BIOPSY 
 
IHC – 
Ki67 
BIOPSY P value 
CERVICITIS CIN I CIN II CINIII SCC 
 
 
0.000 
Neg 2 2 0 0 0 
lower 1/3 0 9 0 0 0 
lower 2/3 0 0 5 0 0 
Full 
thickness 0 0 0 4 0 
Diffuse 0 0 0 0 8  
 
               The Ki-67 expression in ICC and IHC were compared in relation to 
cervical lesions. All cervicitis cases showed concordance in ICC and IHC. 
Among the 11 CIN I cases, 8 cases showed positivity in ICC, and 9 cases 
showed positivity in IHC. All CIN II, CIN III and SCC cases showed 100% 
concordance in ICC and IHC (table 37). 
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TABLE 37  
COMPARISON OF EXPRESSION OF Ki-67 IN ICC AND IHC IN 
RELATION TO CERVICAL LESIONS 
Ki67 
 
BIOPSY 
CERVICITIS CIN I CIN II CIN III SCC 
1CC IHC ICC IHC ICC IHC ICC IHC ICC IHC
NEG 2 2 3 2 0 0 0 0 0 0 
POS 0 0 8 9 5 5 4 4 8 8 
% of 
agreement 100% 88.9% 100% 100% 100% 
 
              The efficacy of LBC and immunocytochemistry with p16 and Ki-
67are compared in table 38 and chart 15. 
 
TABLE 38 
COMPARISON OF EFFICACY OF LBC AND 
IMMUNOCYTOCHEMISTRY WITH p16 AND Ki-67 
 LBC ICC-p16 ICC-Ki67 
Sensitivity 77.78% 88.89% 89.28% 
Specificity 100% 100% 100% 
PPV 33.3% 50% 40% 
NPV 100% 100% 100% 
P value 0.000 0.000 0.000 
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CHRONIC CERVICITIS
Figure 1 : LBC - Mature squamous cells in a background of 
inflammatory cells (Pap stain, 100x)
Figure 2 : Immunocytochemistry
p16 negative, 400x
Figure 3 : Immunocytochemistry Ki-67 
nuclear positivity in normal cells, 100x
CHRONIC CERVICITIS
Figure 4 : Cervical punch biopsy. (H&E stain, 100x)
Figure 5 : Immunohistochemistry
p16 negative, 100x
Figure 6 : Immunohistochemistry
Ki-67 nuclear positivity
 in normal basal cells, 400x
LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION
Figure 7 : LBC - Koilocytotic atypia with 
perinuclear halo. (Pap stain, 400x)
Figure 8 : Immunocytochemistry
p16 weakly positive, 400x
Figure 9 : Immunocytochemistry
Ki-67 nuclear positivity, 400x
CERVICAL INTRAEPITHELIAL NEOPLASIA - I
Figure 10 : Cervical punch biopsy - 
Dysplasia in lower 1/3rd (H&E, 400x)
Figure 11 : Immunohistochemistry
p16 band like positivity
rd
 in lower 1/3 , 100x
Figure 12 : Immunohistochemistry
Ki-67 nuclear positivity
rd
in lower 1/3 , 400x
HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION
Figure 13 : LBC - Cells with increased N:C Ratio and 
irregular  nuclear contour (Pap stain, 400x )
Figure 14 : Immunocytochemistry
p16 strongly positive, 400x
Figure 15 : Immunocytochemistry
Ki-67 nuclear positivity in 
10 to 50% of dysplastic cells, 100x
CERVICAL INTRAEPITHELIAL NEOPLASIA - II
Figure 16 : Cervical punch biopsy - dysplasia in lower 2/3rd
(H&E stain, 100x)
Figure 17 : Immunohistochemistry
rd
p16 positive in lower 2/3 , 100x
Figure 18 : Immunohistochemistry
Ki-67 nuclear positivity
rd
 in lower 2/3 , 400x
CERVICAL INTRAEPITHELIAL NEOPLASIA - III
Figure 19 : Cervical punch biopsy - 
Dysplasia in full thickness of epithelium (H&E, 100x)
Figure 20 : Immunohistochemistry
p16 positive in full thickness, 100x
Figure 21 : Immunohistochemistry
Ki-67 nuclear positivity
 in full thickness, 400x
SQUAMOUS CELL CARCINOMA
Figure 22 : LBC - Cluster of atypical malignant cells
(Pap stain, 400x)
Figure 23 : Immunocytochemistry
p16 strongly positive, 400x
Figure 24 : Immunocytochemistry
Ki-67 nuclear positivity in 
>50% of dysplastic cells, 400x
SQUAMOUS CELL CARCINOMA
Figure 25 : Cervical punch biopsy - 
Invasive squamous cell carcinoma (H&E, 100x)
Figure 26 : Immunohistochemistry
p16 diffuse positivity, 100x
Figure 27 : Immunohistochemistry
Ki-67 nuclear positivity, 100x
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DISCUSSION 
 
 Cervical cancer in developing countries like India is still a major socio-
economic burden, despite the availability of screening procedures. It has been 
said that routine screening can bring down the incidence of carcinoma cervix 
to a great extent(60). And it has also been said that lack of screening is the 
major risk factor for cervical cancer. Hence there is a need for better screening 
procedures. 
 
               Cervical cytology is complicated by inter-observer variability. 
Though there are specific morphological criteria to diagnose cervical 
precancerous and cancerous lesions, this is complicated by inter-observer 
variability and hence lacks sensitivity(61). Co-testing with HPV PCR was 
introduced. But this lacks specificity because most of the HPV infections are 
transient(62,63,64,65,66,67,68). Hence use of immunomarkers in cervical cytology by 
immunocytochemistry was introduced to overcome the problems faced by the 
above said screening procedures. This has been proved to be both highly 
sensitive and specific(69). There are various markers to diagnose cervical 
precancerous and cancerous lesions like p16, HPV L1 capsid, CDC6, MCM5 
etc(69,70). Of these, p16 has been proved to be the most useful and reliable 
marker(70).  
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               In our current study, we studied the association of p16 and Ki-67 
expression in cervical smears of cervical precancerous and cancerous lesions 
and compared their expression with cervical cytology, HPE and the expression 
of same markers in tissue sections (immunohistochemistry). Of these, 
histopathologic examination was taken as the gold standard and the efficacy of 
various screening procedures like cervical cytology, immunocytochemistry 
with p16 and immunocytochemistry with Ki-67 were compared. 
 
EPIDEMIOLOGY OF CERVICAL PRE-NEOPLASTIC AND 
NEOPLASTIC LESIONS IN OUR INSTITUTE  
(FEBRUARY 2014 TO JULY 2014) 
 
               Totally, 202 cases of cervical pre-neoplastic and neoplastic lesions 
were diagnosed during a 6 months period from February 2014 to July 2014 at 
the Institute of Social Obstetrics and Govt. Kasturba Gandhi Hospital for 
Women and Children, Madras Medical College. Of these, 170 were 
colposcopic biopsies, 9 were LLETZ specimens, 13 were random ectocervix 
biopsy specimens and 10 were hysterectomy specimens. The statistics for 6 
months period were as follows, 
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1. Of the 202 cases, 139 were CIN I, 19 were CIN II, 11were CIN III and 
33 were malignancies. So CIN I (68.8%) constituted majority of cases, 
followed by malignancy (16.3%), CIN II (9.4%) and CIN III (5.4%). 
2. Of the 33 malignant cases, 21 were SCC-WD, 10 were SCC-MD, 1 was 
SCC-PD and 1 was adenocarcinoma. So SCC-WD constituted majority 
of cases (63.6%), followed by SCC-MD (30.3%). 
3. Of the 139 CIN I cases, 70 cases (50.4%) were in the 31-40 year age 
group, followed by 38 cases (27.3%) in the 41-50 year age group, 27 
cases (19.4%) in the 21-30 year age group and 4 cases (2.9%) in above 
50 year age group. 
4. Of the 19 CIN II cases, 9 (47.4%) were in the 31-40 year age group. Of 
the 11 CIN III cases, 6 (54.5%) were in the 31-40 year age group. So 
the incidence of all the cervical precancerous lesions was common in 
the age group of 31-40 years. According to a study conducted by 
Bhojani(71), the cervical precancerous lesions were more common in the 
30-39 year age group. 
5. Of the 33 malignant cases, 14 (42.4%) were in the 51-60 year age group, 
followed by 12 cases (36.4%) in the 41-50 year age group, 4 (12.1%) in 
the above 60 year age group. Only 3 cases (9.1%) were in the 31-40 
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year age group. So malignancy was common in women above 40 years. 
According to a study conducted by Satya B. Paul et al(72), the incidence 
of cervical carcinoma was more common in the 41-50 year age group. 
6. Cervical precancerous lesions were found to be more common in the 
reproductive women (CIN I – 88.5%, CIN II – 73.7%, CIN III – 
81.8%), whereas malignancy was found to be more common in the 
post-menopausal women (90.9%). 
7. Majority (58.3%) of cervical precancerous lesions were seen in the 12-3 
o’ clock quadrant of the cervix. Majority of the carcinoma cases 
(96.1%) were seen circumferentially abutting the os. 
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THE CURRENT STUDY GROUP 
 
               This was a prospective study involving 30 patients. 30 VIA/VILI 
positive cases were randomly selected from the patients attending the 
colposcopy department of the Institute of Social Obstetrics and Govt. Kasturba 
Gandhi Hospital for Women and Children, Madras Medical College for our 
study. These 30 patients were then subjected to liquid based cervical cytology 
and cervical biopsy. Immunocytochemistry with p16 and Ki-67 in cervical 
smears and immunohistochemistry with p16 and Ki-67 in tissue sections were 
performed. These procedures were compared with each other taking biopsy 
diagnosis as the gold standard.  
 
 Of the 30 VIA/VILI positive cases, 15 were low grade lesions, 10 were 
high grade lesions and 5 were interpreted as invasive carcinoma. The 15 low 
grade lesions (LGL) in VIA/VILI turned out to be cervicitis – 2, CIN I – 10, 
CIN II – 3 by histopathologic examination. Thus 2 cases which were 
VIA/VILI positive turned out to be cervicitis (false positive). 10 high grade 
lesions (HGL) in VIA/VILI turned out to be CIN I – 1, CIN II – 2, CIN III – 4 
and SCC – 3 in biopsy. 3 squamous cell carcinomas were underestimated as 
high grade lesions in VIA/VILI. All the 5 invasive carcinomas were reported 
as squamous cell carcinoma in biopsy. 
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               The percentage of concordance for VIA/VILI with biopsy was 66.7% 
for LGL, 90% for HGL and 100% for SCC in this study group. Thus 
VIA/VILI was more sensitive in detecting high grade lesions and malignancy 
than low grade lesions. 
 
CHARACTERISTICS OF THE STUDY GROUP 
1. Of the 30 cases, 2 patients diagnosed with chronic cervicitis by biopsy 
were in the 21-30 year age group. Majority of CIN I lesions were in the 
31-40 year age group (54.5%). CIN II/III lesions were also common in 
31-40 year age group (33.3%), followed by equal distribution among 
the 21-30, 41-50 and 51-60 year age groups. All 8 cases of squamous 
cell carcinomas were in the 41-60 year age group.  
2. Majority of the cervical non-neoplastic and pre-neoplastic lesions 
(81.8%) were seen in reproductive women. But all the squamous cell 
carcinoma cases (100%) were seen in the post-menopausal women.  
3. Majority of cervical precancerous lesions (63.6%) were in the 12-3 o’ 
clock quadrant of the cervix. All the carcinoma cases were seen 
circumferentially abutting the os. 
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LIQUID BASED CERVICAL CYTOLOGY 
 
 The cervical cytology reports of the 30 cases were given as negative for 
intraepithelial lesion (NIL) – 6, low grade squamous intraepithelial lesion 
(LSIL) – 10, high grade squamous intraepithelial lesion (HSIL) – 8 and 
squamous cell carcinoma (SCC) – 6. These reports were then compared with 
the HPE diagnosis.  
 
 The 6 NIL cases turned out to be 2 cervicitis and 4 CIN I by biopsy. 
Thus 4 NIL cases were false negative. 10 LSIL cases turned out to be 7 CIN I 
and 3 CIN II by biopsy. 9 HSIL cases turned out to be 2 CIN II, 4 CIN III and 
3 SCC in biopsy. All 5 SCC cases were proved to be SCC in biopsy. The 
percentage of concordance for LBC with biopsy was 33.3% for NIL, 70% for 
LSIL, 75% for HSIL and 100% for SCC. Thus the cytology reports were more 
concordant for high grade lesions than low grade lesions. 
 
 The correlation of grading cervical lesions by morphological criteria in 
cervical cytology with the biopsy diagnosis was statistically significant 
showing P value of 0.000   
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 The sensitivity of liquid based cervical cytology in diagnosing the 
cervical pre-neoplastic and neoplastic lesions was 77.78%, specificity was 
100%, positive predictive value was100% and negative predictive value was 
33.33% in our study. This is compared with other studies in table 39. 
 
TABLE 39 
COMPARISON OF EFFICACY OF LBC WITH OTHER STUDIES 
 SENSITIVITY SPECIFICITY PPV NPV 
Our study 77.78% 100% 100% 33.33% 
Singh KN et al (73) 70.02% 97.2% 51.2% 97% 
Divya Hedge et al (74) 83% 98% 97.9% 80% 
Rana T et al (75) 83.3% 97% 83% 97% 
Shankaranarayanan 
et al (78) 86% 91% 22% 99% 
 
 
 
 
 
 
83 
 
IMMUNOCYTOCHEMISTRY 
 
p16INK4a EXPRESSION 
 p16INK4a showed nuclear or cytoplasmic positivity or both. This was 
reported as positive or negative. But in some studies (89), all low grade lesions 
showed faint or weak positivity and all high grade lesions showed strong and 
diffuse positivity. And hence in our study, an attempt to study the significance 
of correlation of intensity of p16 staining with increasing grades of cervical 
lesions was done. Hence scoring was given as follows based on intensity of 
staining. 
 0 – negative 
 1 – weakly positive in dysplastic cells 
 2 – strongly positive in dysplastic cells 
              The results were 4 negative cases, 12 weakly positive cases and 14 
strongly positive cases. 
 
COMPARISON WITH CYTOLOGY 
 The expression of p16, when compared with morphologic diagnosis of 
cells in cervical smears showed the following results. Among the 6 NIL cases, 
4 (66.7%) were negative and 2 were weakly positive. Among the 10 LSIL 
cases, 9 (90%) cases showed weak positivity and 1 showed strong positivity. 
Among the 8 HSIL cases, 1 showed weak positivity and 7 cases (87.5%) 
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showed strong positivity. All 6 carcinoma cases in cytology showed strong 
positivity with p16.  
 
 Carmen Ungureanu et al(77) found p16 positivity in 16.66% of ASCUS 
(1/6), 40.62% of LSIL (13/32), 96.29% of HSIL (26/27) and 100% of SCC 
cases. All NIL cases were negative with p16. 
 
 According to a study conducted by Ingrid Norman et al(80), 33% of 
ASCUS cases showed weak positivity with p16, 17% and 9.8% of LSIL cases 
showed weak and moderate staining with p16 respectively and 20%, 49% and 
20% of HSIL cases showed weak, moderate and strong staining with p16 
respectively. 
 
 In a study conducted by CD Izaaks et al(82), 5/28 (17.9%) cases with 
ASCUS, 7/9 (77.8%) cases with ASC-H, 50/96 (52.1%) cases with LSIL and 
51/54 (94.4%) cases with HSIL showed positivity with p16 in cervical smears. 
 
 In our study, 4 cases diagnosed as NIL by cytology turned out to be CIN 
I in biopsy. Of these, 2 have been detected by p16 in cervical smear thus 
increasing the sensitivity of cervical cytology.  
 
COMPARISON WITH HPE 
 The expression of p16 in cervical smears was compared with biopsy 
diagnosis. All cervicitis cases showed negativity with p16. 81.8% of CIN I and 
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100% of CIN II, CIN III and SCC cases showed positivity with p16. This 
association was statistically significant (P value = 0.000). 
 
               According to a study conducted by Tsoumpou I et al(79), 2% of 
normal cervix and 38% of CIN I, 68% of CIN II and 82% of CIN III showed 
positivity with p16 in cervical smears. 
 
 In a study conducted by N Murphy et al(81), all 12 normal smears were 
negative for p16, all 5 CIN I, 6 of 7 CIN II and all 8CIN III cases showed 
positivity with p16 in Thin Prep smears. 
 
 In a study conducted by Nicolas Wetzensen et al(83), p16/Ki-67 showed 
positivity in 26.8% of normal smears, 46.5% of CIN I, 82.8% of CIN II and 
92.8% of CIN III cases. 
 
 In our study, the sensitivity (88.89%) and the negative predictive value 
(50%) for the use of p16 in cervical smears (ICC) were increased when 
compared to morphological diagnosis of cells in cervical smears (cervical 
cytology). The specificity and the positive predictive value remained 100% for 
immunocytochemistry with p16, similar to that of cytology. This is compared 
with other studies in table 40. 
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TABLE 40 : COMPARISON OF EFFICACY OF ICC WITH p16 WITH 
OTHER STUDIES 
 SENSITIVITY SPECIFICITY PPV NPV 
Our study 88.89% 100% 100% 50% 
Carmen et al(77) 100% 76.74% 76.7% 100% 
Indigo Norman et 
al(80) 60% 100% 100% - 
CD Izaaks et al(82) 96.4% 54% 60.4% 40% 
Nicolas et al (83) 90.6% - 48.6% - 
 
INTENSITY OF p16 EXPRESSION 
 In addition to this, the intensity of expression of p16 also showed an 
association with increasing grades of cervical pre-neoplastic and neoplastic 
lesions. Majority of the cases diagnosed as LSIL in cytology showed weak 
positivity (90%) and 1 showed strong positivity.  Majority of cases (87.5%) 
diagnosed as HSIL and 100% of cases diagnosed as malignancy in cytology 
showed strong positivity with p16. Thus the intensity of expression of p16 in 
cervical smears increased with increasing grades of cervical pre-neoplastic and 
neoplastic lesions in cytology. 
 
 When compared with biopsy, all the 9 CIN I cases showed weak 
positivity with p16 in dysplastic cells in cervical smears. Among the 5 CIN II 
cases, 3 (60%) were strongly positive and 2 were weakly positive. Among the 
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4 CIN III cases, 3(75%) were strongly positive and 1 was weakly positive. All 
the 8 SCC cases (100%) showed strong positivity. The correlation of 
increasing intensity of p16 expression in cervical smears with HPE diagnosis 
of cervical lesions showed P value of 0.000 which was statistically significant.  
 
 Thus the increasing intensity of p16 expression in cervical smears was 
found to have an association with increasing grades of cervical lesions. 
 
 This was also proved by Ingrid Norman et al(80) who found a correlation 
between intensity of p16expression and CIN grade. Benign cases and most of 
the low grade lesions showed no or weak reactivity and most of the high grade 
lesions showed moderate or strong reactivity with p16 in cervical smears. 
 
COMPARISON WITH IMMUNOHISTOCHEMISTRY 
 In tissue sections, p16 expression was reported as positive or 
negative(90). All cervicitis cases showed negativity with p16 in tissue sections. 
Among the 11 CIN I cases, 9 showed positivity and 2 were negative. All the 5 
CIN II cases, all the 4 CIN III cases and all the 8 SCC cases showed positivity 
for p16. The correlation of immunohistochemical p16 expression with biopsy 
showed a P value of 0.003 which was statistically significant. 
 
 Also the expression of p16 in cervical smears (ICC) showed 100% 
concordance with their expression in tissue sections (IHC). 
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 It was found that majority of CIN I cases which were positive showed 
moderate p16 expression in lower 1/3rd of the epithelium like a band. And all 
high grade lesions showed diffuse and strong positivity occupying the lower 
2/3rd to full thickness of the epithelium. The malignant cases showed diffuse 
and strong positivity in almost all of the malignant cells. This was also proved 
by Maria Carolina et al(90). 
 
Ki-67 EXPRESSION 
 Ki-67 showed nuclear staining. As even normal proliferating basal cell 
layer of cervical lining shows positivity with Ki-67, positivity in <1% of 
normal cells was taken as negative. Hence Ki-67 positivity in dysplastic cells 
was counted. Ki-67 expression in cervical smears were graded as follows(88), 
 0 – negative 
 1 – <10% of dysplastic cells 
 2 – 10-50% of dysplastic cells 
 3 – >50% of dysplastic cells 
 
 In our study, 5 cases were negative, 7 cases showed positivity in <10% 
of dysplastic cells, 10 cases showed positivity in 10-50% of dysplastic cells 
and 8 cases showed positivity in >50% of dysplastic cells. 
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COMPARISON WITH CYTOLOGY 
 Among the 6 NIL cases diagnosed by LBC, 5 (83.3%) showed 
negativity (<1% of normal cells positive) with Ki-67 and 1 showed positivity 
in <10% of dysplastic cells. Among the 10 LSIL cases, 6 (60%) showed 
positivity in <10% of dysplastic cells and 4 (40%) showed positivity in 10-
50% of dysplastic cells. Among the 8 HSIL cases, 5 (62.5%) showed positivity 
in 10-50% of dysplastic cells and 3 (37.5%) showed positivity in >50% of 
dysplastic cells. Among the 6 SCC cases, 5 (83.3%) showed positivity in 
>50% of dysplastic cells and 1 showed positivity in 10-50% of dysplastic cells. 
Thus with increasing grades, the percentage of dysplastic cells expressing Ki-
67 in cervical smears also increased. 
 
COMPARISON WITH HPE 
 2 cervicitis cases diagnosed by biopsy showed positivity in <1% of 
normal cells in cervical smears which was taken as negative. Of the 11 CIN I 
cases, 3 cases were negative and 8 cases (72.7%) showed positivity. Of the 8 
positive cases, 6 showed positivity in <10% of dysplastic cells and 2 showed 
positivity in 10-50% of dysplastic cells. All the CIN II cases showed positivity, 
of which 1showed positivity in <10% of dysplastic cells, 3showed positivity in 
10-50% of dysplastic cells and 1 showed positivity in >50% of dysplastic cells. 
All the 4 CIN III cases showed positivity, of which 3 showed positivity in 10-
50% of dysplastic cells and 1 showed positivity in >50% of dysplastic cells. 
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All the 8 SCC cases were positive, of which 2 showed positivity in 10-50% of 
dysplastic cells and 6 showed positivity in >50% of dysplastic cells. Thus the 
percentage of dysplastic cells expressing Ki-67 increased with increasing 
grades of cervical lesions. This was statistically significant showing P value of 
0.000 
 
 In a study conducted by Nicolas Wetzensen et al (83), p16/Ki-67 showed 
positivity in 26.8% of normal smears, 46.5% of CIN I, 82.8% of CIN II and 
92.8% of CIN III cases. 
 
 The sensitivity of use of Ki-67 in cervical smears was 89.28% and 
negative predictive value was 40%, which were more than that of cervical 
cytology. The specificity and the positive predictive value were 100%, similar 
to that of cervical cytology. This is compared with other studies in table 41. 
 
TABLE 41 : COMPARISON OF EFFICACY OF ICC WITH Ki-67 
WITH OTHER STUDIES 
 SENSITIVITY SPECIFICITY PPV NPV 
Our study 89.28% 100% 100% 40% 
Nicolas et al(83) 90.6% - 48.6% - 
S Sahebali et 
al(84) 95% 95% - - 
S W Byun et 
al(85) 76.2% 51.4% 48.5% 78.3% 
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 Many of the inflammatory cases, reactive atypias and even normal 
smears showed positivity in less than 1% of normal cells. But p16 showed no 
such expression in non-neoplastic lesions. This was also proved by S. Nicholas 
Agoff et al (85). So Ki-67 expression in <1% of normal cells was taken as 
negative.  
 
 Ki-67, when done along with p16 as dual staining in cervical smears can 
help to distinguish cervicitis and low grade lesions like CIN I. This dual 
staining with p16 and Ki-67 was studied in cervical smears by Nicolas 
Wetzensen et al (83). It showed positivity in 19.6% of NIL, 40.2% of ASC-US, 
68.8% of LSIL, 82.5% of ASC-H, and 95.3% of HSIL cases. A study 
conducted by Petry KU et al (87) showed 91.9% sensitivity and 82.1% 
specificity for p16/Ki-67 dual staining. This was also studied by Seung Won 
Byun et al (85). 
 
 Lesions above CIN II till malignancy showed a mixture of cases 
expressing Ki-67 in 10-50% and >50% of dysplastic cells. 
 
 Thus Ki-67 (ICC) can be used to distinguish high grade lesions from 
low grade lesions in cervical smears. But it is difficult to distinguish cervicitis 
from CIN I using Ki-67 alone in some cases. 
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COMPARISON WITH IMMUNOHISTOCHEMISTRY 
 In tissue sections, cases expressing Ki-67 in nuclei of the basal cells 
were taken as negative as it is normal. Only those cases expressing Ki-67, 2 
layers above the basal layer were considered as positive(91,92,93). The 2 cases of 
cervicitis showed Ki-67 expression only in the basal layer and hence reported 
as negative. Of the 11 CIN I cases, 2cases were negative and the remaining 9 
cases showed nuclear positivity in lower 1/3rd of the epithelium. All the 5 CIN 
II cases showed nuclear positivity in lower 2/3rd of the epithelium. All the 4 
CIN III cases showed nuclear positivity in full thickness of the epithelium. All 
the 8 SCC cases showed nuclear positivity diffusely in the malignant cells 
including the invasive component. The association of thickness of epithelium 
showing Ki-67 expression in tissue sections (IHC) in cervical non-neoplastic, 
pre-neoplastic and neoplastic lesions showed P value of 0.000 which was 
statistically significant. This was also proved by Maria Carolina et al (90). 
 
 18.2% of CIN I lesions were negative for Ki-67 in tissue sections, like 
that in cervical smears overlapping with the features of cervicitis. This when 
combined with p16 helped to distinguish cervicitis and CINI.  
 
 The percentage of concordance for Ki-67 expression in ICC with IHC 
was 100% for cervicitis, 88.9% for CIN I, 100% for CIN II, 100% for CIN III 
and 100% for SCC cases. 
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COMPARISON OF EFFICACY OF LBC AND 
IMMUNOCYTOCHEMISTRY IN OUR STUDY 
 
 The efficacy of cervical cytology and immunocytochemistry with p16 
and Ki-67 are compared in table 42. 
 
TABLE 42 
COMPARISON OF EFFICACY OF LBC AND 
IMMUNOCYTOCHEMISTRY WITH p16 AND Ki-67 
 LBC ICC-p16 ICC-Ki67 
Sensitivity 77.78% 88.89% 89.28% 
Specificity 100% 100% 100% 
PPV 33.3% 50% 40% 
NPV 100% 100% 100% 
P value 0.000 0.000 0.000 
 
               Thus the use of immunomarkers in cervical smears was found to 
definitely increase the sensitivity from 77.78% for cervical cytology 
interpreted by morphological criteria to 89%. The specificity was found to be 
100% for both in our study. 
 
 
94 
 
 As lack of diagnosis of cervical carcinogenesis in early stages is 
currently the major risk factor for cervical cancer, there is a need to use 
screening procedures with better sensitivity for early detection. In our study, 
immunocytochemistry using p16INK4a and Ki-67 has been proved to hold a 
higher sensitivity. Hence immunocytochemistry can be used as a screening 
tool in routine cervical cancer screening. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
SUMMARY 
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SUMMARY 
1. Totally, 202 cases of cervical pre-neoplastic and neoplastic lesions were 
diagnosed during a 6 months period from February 2014 to July 2014 at 
the Institute of Social Obstetrics and Govt. Kasturba Gandhi Hospital 
for Women and Children, Madras Medical College.  
 
2. Of these, 170 were colposcopic biopsies, 9 were LLETZ specimens, 13 
were random ectocervix biopsy specimens and 10 were hysterectomy 
specimens. 
 
3. Of the 202 cases, CIN I (68.8%) constituted majority of cases, followed 
by malignancy (16.3%), CIN II (9.4%) and CIN III (5.4%). 
 
4. Of the 33 malignant cases, SCC-WD constituted majority of cases 
(63.6%), followed by SCC-MD (30.3%), SCC-PD (3%) and 
adenocarcinoma (3%). 
 
5. The incidence of all the cervical precancerous lesions was common in 
the 31-40 year age group. Malignant cases were common in the 51-60 
year age group. 
 
6. Cervical precancerous lesions were found to be more common in the 
reproductive women (CIN I – 88.5%, CIN II – 73.7%, CIN III – 81.8%), 
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whereas malignancy was more common in the post-menopausal women 
(90.9%). 
 
7. Majority (58.3%) of cervical precancerous lesions were seen in the 12-3 
o’ clock quadrant of the cervix. Majority of the carcinoma cases (96.1%) 
were seen circumferentially abutting the os. 
 
8. In our study group involving 30 patients, the percentage of concordance 
for VIA/VILI with biopsy was 66.7% for LGL, 90% for HGL and 100% 
for SCC. 
 
9. The percentage of concordance for LBC with biopsy was 33.3% for 
NIL, 70% for LSIL, 75% for HSIL and 100% for SCC. Thus the 
cytology reports were more concordant for high grade lesions than low 
grade lesions. 
 
10. The correlation of grading cervical lesions by morphological criteria in 
cervical cytology with the biopsy diagnosis was statistically significant 
showing P value of 0.000   
 
11. The sensitivity of liquid based cervical cytology was 77.78%, specificity 
was 100%, positive predictive value was100% and negative predictive 
value was 33.33% 
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12. By immunostaining with p16 in cervical smears, 4 (66.7%) NIL cases 
were negative and 2 were weakly positive. 90% of LSIL cases showed 
weak positivity. 87.5% of HSIL and100% of SCC cases showed strong 
positivity. Among the 4 CIN I cases diagnosed as NIL by cytology, 2 
have been detected by p16 in cervical smear thus increasing the 
sensitivity of cervical cytology. 
 
13. When compared with HPE, all cervicitis cases showed negativity with 
p16 in cervical smears (ICC). 81.8% of CIN I and 100% of CIN II, CIN 
III and SCC cases showed positivity with p16 in cervical smears. This 
association was statistically significant (P value = 0.000). 
 
14. All the 9 p16 positive CIN I cases showed weak positivity in dysplastic 
cells in cervical smears (ICC). 60% of CIN II, 75% of CIN III and 100% 
of SCC cases showed strong positivity. The correlation of increasing 
intensity of p16 expression in cervical smears with HPE diagnosis in 
cervical lesions showed P value of 0.000 which was statistically 
significant. 
 
15. The sensitivity (88.89%) and the negative predictive value (50%) for 
immunocytochemistry with p16 increased when compared to cervical 
cytology. The specificity and the positive predictive value remained 
100%, similar to that of cytology. 
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16. In tissue sections, p16 expression in CIN I showed weak band like 
positivity in the lower third of epithelium. In high grade lesions, p16 
showed strong and diffuse positivity in 2/3rd to full thickness of 
epithelium. All the malignant cases showed diffuse and strong positivity 
in the malignant cells. 
 
17. The correlation of immunohistochemical p16 expression with biopsy 
showed a P value of 0.003 which was statistically significant. 
 
18. The expression of p16 in cervical smears (ICC) showed 100% 
concordance with their expression in tissue sections (IHC). 
 
19. By immunostaining with Ki-67 in cervical smears, 83.3% of NIL cases 
showed negativity (positive in <1% of normal cells). 60% of LSIL cases 
showed positivity in <10% of dysplastic cells and 40% in 10-50% of 
dysplastic cells. 62.5% of HSIL cases showed positivity in 10-50% of 
dysplastic cells and 37.5% in >50% of dysplastic cells. 83.3% of SCC 
cases showed positivity in >50% of dysplastic cells. Thus with 
increasing grades, the percentage of dysplastic cells expressing Ki-67 in 
cervical smears also increased. 
 
20. When compared with biopsy, 2 cervicitis cases were negative with Ki-
67 (positive in <1% of normal cells) in cervical smears (ICC). 72.7% of 
CIN I cases showed positivity, most of them in <10% of dysplastic cells. 
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60% of CIN II and 75% CIN III cases showed positivity in 10-50% of 
dysplastic cells. 75% of SCC cases showed positivity in >50% of 
dysplastic cells. Thus with increasing grades, the percentage of 
dysplastic cells expressing Ki-67 in cervical smears also increased. This 
was statistically significant showing P value of 0.000 
 
21. The sensitivity of use of Ki-67 in cervical smears was 89.28% and 
negative predictive value was 40%, which were more than that of 
cervical cytology. The specificity and the positive predictive value were 
100%, similar to that of cervical cytology. 
 
22. In tissue sections, 2 cases of cervicitis showed Ki-67 nuclear expression 
only in the basal layer and hence reported as negative. Of the 11 CIN I 
cases, 2 cases were negative and the remaining 9 cases showed nuclear 
positivity in lower 1/3rd of the epithelium. All the 5 CIN II cases showed 
nuclear positivity in lower 2/3rd of the epithelium. All the 4 CIN III 
cases showed nuclear positivity in full thickness of the epithelium. All 
the 8 SCC cases showed diffuse nuclear positivity in the malignant cells 
including the invasive component. The association of thickness of 
epithelium showing Ki-67 expression in tissue sections (IHC) in cervical 
non-neoplastic, pre-neoplastic and neoplastic lesions showed P value of 
0.000 which was statistically significant. 
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23. The percentage of concordance for Ki-67 expression in ICC with IHC 
was 100% for cervicitis, CIN II, CIN III and malignancy, but 88.9% for 
CIN I. 
 
24. Many of the inflammatory cases, reactive atypias and even normal 
smears showed Ki-67 nuclear positivity in less than 1% of normal cells. 
But p16 showed no such expression in non-neoplastic lesions. Ki-67 
when combined with p16 helped to distinguish cervicitis and CIN I. 
 
25. Thus the use of immunomarkers in cervical smears was found to 
definitely increase the sensitivity from 77.78% for cervical cytology by 
routine pap staining to 89%. The specificity was found to be 100% for 
both in our study. 
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CONCLUSION 
 
 The sensitivity of cervical cytology was 77.78% and specificity was 
100% in our study. As lack of cervical cancer screening is the major risk factor 
for cervical carcinoma now, it is of utmost importance to increase the 
sensitivity of present day screening procedures, so that cervical precancerous 
lesions can be diagnosed at an early stage and appropriately treated, thus 
reducing the incidence of cervical carcinoma.  
 
 The use of immunomarkers like p16INK4a and Ki-67 in cervical smears 
showed sensitivity of 88.89% and 89.28% respectively and specificity of 
100%. Thus even cases that cannot be morphologically diagnosed in cytology 
can be detected by immunocytochemistry. 
 
 In addition to this, the intensity of p16 expression and percentage of 
cells expressing Ki-67 in cervical smears can be used to grade cervical pre-
neoplastic and neoplastic lesions whose association was found to be 
statistically significant in our study. 
 
 The limitation of use of Ki-67 in cervical smears is that they show 
positivity even in normal basal cells and in cases of inflammation, reactive 
atypia etc. p16 showed no such expression. By using dual staining for p16 and 
Ki-67 or by simply combining the results of p16 and Ki-67 expression, this 
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limitation can be overcome and cervical non-neoplastic and low grade lesions 
can be distinguished. 
 
 The use of immunomarkers in cervical smears has significantly 
increased the sensitivity of cervical cancer screening in our study as well as in 
many other studies all over the world. Hence steps should be taken to 
incorporate immunocytochemistry in cervical cancer screening in areas with 
better financial and laboratory resources, thus further bringing down the 
incidence and burden of cervical carcinoma. 
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 ANNEXURE II : PROFORMA 
 
NAME: 
AGE: 
CYTOLOGY NO. : 
BIOPSY NO. :  
PRESENTING COMPLAINTS: 
H/o white discharge  :  Yes/No 
H/o bleeding PV   : Yes/No 
H/o post coital bleeding  : Yes/No  
 
MENSTRUAL HISTORY: 
Age at menarche : 
Age at marriage : 
H/o pregnancy : 
LMP   : 
Menstrual cycle : 
Age at menopause : 
 
PRIOR TREATMENT HISTORY: 
 H/o prior Cryotherapy/ Cervical biopsy/ LLETZ/ Conisation/ 
  Hysterectomy/ Radiation : Yes/No 
 COITAL HISTORY: 
H/o IUD use    : Yes/No 
H/o Sexual intercourse with spermicidal jelly,  
douches/tampons 24 hours prior : Yes/No 
 
COLPOSCOPY FINDINGS: 
Gross    : 
VIA    : 
VILI    : 
Quadrant of cervix  : 
 
 
 
 
 
 
 
 
 
 
 
 ANNEXURE III 
WHO CLASSIFICATION OF TUMOURS OF THE UTERINE 
CERVIX – EPITHELIAL TUMOURS 
 
SQUAMOUS TUMOURS AND PRECURSORS 
 SQUAMOUS CELL CARCINOMA, NOT OTHERWISE SPECIFIED 
- Keratinizing 
- Non-keratinizing 
- Basaloid 
- Verrucous 
- Warty 
- Papillary 
- Lymphoepithelioma-like 
- Squamotransitional 
 
 EARLY INVASIVE (MICROINVASIVE) SQUAMOUS CELL 
CARCINOMA 
 
 SQUAMOUS INTRAEPTHELIAL NEOPLASIA 
- Cervical intraepithelial neoplasia (CIN) 3/ squamous cell carcinoma 
in situ 
 
 BENIGN SQUAMOUS CELL LESIONS 
- Condyloma acuminatum 
- Squamous papilloma 
- Fibroepithelial polyp 
 ANNEXURE IV 
THE BETHESDA SYSTEM 2001 
 
Specimen Type:  
Conventional Smear (Pap Smear) vs Liquid-Based Preparations vs Other 
 
Specimen adequacy 
Satisfactory for evaluation 
Unsatisfactory for evaluation 
 
General categorization (optional) 
Negative for intra-epithelial lesion or malignancy 
Epithelial cell abnormality 
Other  
 
Automated review 
Ancilliary testing 
Interpretation/result 
Negative for intra-epithelial lesion or malignancy 
Epithelial cell abnormalities 
Squamous cell 
 Atypical squamous cells 
     -of undetermined significance 
     -cannot exclude high-grade squamous intra-epithelial lesion (HSIL) 
 Low-grade squamous intra-epithelial lesion  
 High-grade squamous intra-epithelial lesion 
 Squamous-cell carcinoma 
 Glandular cell 
 Atypical 
- Endocervical cells (not otherwise specified [NOS] or specify in 
comments) 
- Endometrial cells (NOS or specify in comments) 
- Glandular cells (NOS or specify in comments) 
 Atypical 
- Endocervical cells, favor neoplastic 
- Glandular cells, favor neoplastic 
 Endocervical adenocarcinoma in situ 
 Adenocarcinoma 
- Endocervical 
- Endometrial 
- Extrauterine 
- NOS 
 
Other malignant neoplasms: (specify) 
Educational notes and suggestions (optional) 
 
 ANNEXURE V 
 
IMMUNOCYTOCHEMISTRY 
MATERIALS REQUIRED 
 PBS (phosphate buffer solution) 
      Sodium chloride – 8g 
      Disodium hydrogen phosphate – 8.3g 
      Potassium dihydrogen phosphate – 1.25g 
      Distilled water – 1000ml 
PROCEDURE 
1. Position slides in slide holders with filter cards and sample chambers and 
attach to cytocentrifuge rotor. 
2. Prepare cell suspension of 500 cells/mm3 with PBS (Preparations that 
are too dilute for cytocentrifugation may be dropped with a pipet using 
the location of the filter card as a guide and allowed to dry). 
3. Add 0.1 ml cell suspension to chamber and centrifuge at 1000 rpm for 5 
minutes (It is important to get just the right amount of speed for 
cytocentrifugation, as too much speed will flatten the cell, and too little 
will not allow the cells to adequately bind to the slide). 
4. Remove slide and immediately dip in 95% ethanol, 5% glacial acetic 
acid fixative for 2 minutes. 
5. Rinse 3x5 min with PBS to remove fixative. 
6. Incubate the slides with 0.25-0.5% Triton X-100 in PBS for 10 minutes 
to permeabilize the membranes (There is no need for a permeabilization 
step following acetone or methanol fixation). 
7. Rinse 3x5min in PBS to remove detergents. 
8. Blocking endogenous peroxidase using 3% H2O2 for 10-30 minutes. 
9. Rinse 3x5 min in PBS. 
10. Incubate with power block for 10 minutes. 
11. Incubate with primary antibody for 1 hour. 
12. Rinse 3x5 min in PBS. 
13. Incubate with antibody amplifier for 15 minutes. 
14. Rinse 3x5 min in PBS. 
15. Incubate with HRP polymer for 30 minutes. 
16. Rinse 3x5 min in PBS. 
17. Incubate with freshly prepared chromogen for 5 minutes. 
18. Rinse for 2 minutes in distilled water. 
19. Dip in Harris Hematoxylin and keep in running tap water for bluing.  
20. Slides are cleared and mounted and analysed under light microscopy. 
 ANNEXURE VI 
 
IMMUNOHISTOCHEMISTRY 
MATERIALS REQUIRED 
 Phosphate buffer solution 
 Retrieval buffer  - Tris buffered solution 
- Tris – 6.05g 
- EDTA – 0.744g 
- Distilled water – 1000ml 
PROCEDURE 
1. Clear in xylene for 30 minutes and dehydrate in alcohol for 10 minutes. 
2. Wash in running tap water for 10 minutes. 
3. Rinse in distilled water for 5 minutes. 
4. Place the slides in Tris buffer and keep it in microwave oven in the 
following temperatures for antigen retrieval 
 640 watts – 5 minutes 
 800 watts – 5 minutes 
 800 watts – 5 minutes 
 800 watts – 3 minutes 
5. Take out the bowl and cool the slides to room temperature. 
6. Rinse 2x5 min in distilled water. 
7. Block endogenous peroxidase using 3% H2O2 for 10-30 minutes. 
8. Rinse 3x5 min in PBS. 
9. Incubate with power block for 10 minutes. 
10. Incubate with primary antibody for 1 hour. 
11. Rinse 3x5 min in PBS. 
12. Incubate with antibody amplifier for 15 minutes. 
13. Rinse 3x5 min in PBS. 
14. Incubate with HRP polymer for 30 minutes. 
15. Rinse 3x5 min in PBS. 
16. Incubate with freshly prepared chromogen for 5 minutes. 
17. Rinse for 2 minutes in distilled water. 
18. Dip in Harris Hematoxylin and keep in running tap water for bluing.  
19. Slides are cleared and mounted and analysed under light microscopy. 
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KEY TO MASTER CHART 
 
AGE: Entered in years 
SITE OF LESION: 
I   – 12-3 o’ clock quadrant 
II   – 3-6 o’ clock quadrant 
III  – 6-9 o’ clock quadrant 
IV  – 9-12 o’ clock quadrant 
V   – Circumferential 
 
CYTOLOGY 
NIL   – Negative for Intra-epithelial Lesion 
LSIL  – Low grade Squamous Intra-epithelial Lesion 
HSIL  – High grade Squamous Intra-epithelial Lesion 
SCC  – Squamous Cell Carcinoma 
 
TYPE OF SPECIMEN 
I   – Colposcopy 
II   – LLETZ  
III   – Ectocervix biopsy 
IV   – Hysterectomy    
 
HPE DIAGNOSIS 
CIN I  – Cervical Intra-epithelial Neoplasia I 
CIN II  – Cervical Intra-epithelial Neoplasia II 
CIN III  – Cervical Intra-epithelial Neoplasia III 
SCC-WD  – Squamous Cell Carcinoma-Well Differentiated 
SCC-MD  – Squamous Cell Carcinoma-Moderately Differentiated 
SCC-PD  – Squamous Cell Carcinoma-Poorly Differentiated 
 
 
ICC – IMMUNOCYTOCHEMISTRY – p16 
0  – negative 
1  – weakly positive in dysplastic cells 
2  – strongly positive in dysplastic cells 
 
ICC – IMMUNOCYTOCHEMISTRY – Ki-67 
0  – negative 
1  – <10% of dysplastic cells positive 
2  – 10-50% of dysplastic cells positive 
3  – >50% of dysplastic cells positive 
 
IHC – IMMUNOHISTOCHEMISTRY – p16 
0  – negative 
1  – positive 
 
IHC – IMMUNOHISTOCHEMISTRY – Ki-67 
0  – negative  
1  – nuclear positivity in lower-third of epithelium 
2  – nuclear positivity in lower two-thirds of epithelium 
3  – nuclear positivity in lower two-thirds to full thickness of  
    epithelium 
4  – diffuse nuclear positivity in the malignant cells 
